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PROGNOSTIC INDICATORS OF MORBIDITY AND MORTALITY IN 
NON DIABETIC SOFT TISSUE INFECTIONS 
Introduction  
Soft tissue skin infections (SSTI’s) were first described in the Hippocratic 
era. The principles of management, including early diagnosis with prompt and 
repeated surgical debridement, aggressive resuscitation and physiological support, 
broad spectrum antimicrobial drugs, and nutritional support, have been well 
documented. Despite this well accepted management approach, the mortality rate 
remains between 16 – 34% in most major published series. Due to the lack of 
defined criteria to determine the type of treatment that has to be given for patients 
at the time of admission, most patients undergo multiple surgical procedures which 
increases the morbidity and mortality.  
Aim of the study 
The primary objective of this analysis is to create a simple clinical score to 
aid in the prediction of morbidity defined by the number of days of hospital stay or 
limb loss and mortality in patients with SSTIs at the time of first assessment. The 
scoring system may further be used to predict limb loss at first assessment, thereby 
reducing multiple surgeries for the same patient. 
Methods 
A retrospective review of 200 consecutive patients with necrotizing soft 
tissue infections, treated at Rajiv Gandhi Government General Hospital during a 1-
year period, was conducted. Using a model for logistic regression analysis, 
characteristics of each patient and his/her clinical course were tested for impact on 
outcome. The variables which were found to independently alter the outcome were 
used to establish a scoring system. This was then applied to a prospective pool of 
50 patients admitted over 6 months in the same hospital. 
Results 
The scoring system decreased the number of surgeries undergone by each 
patient significantly. The scoring system also reduced the number of days of 
hospital stay per patients, though not significantly. The use of the scoring system 
did not alter the mortality in any way.  
Conclusion 
Skin and soft tissue infections of the limbs have a high mortality and 
morbidity especially if necrosis is present. The morbidity is in the form of 
prolonged hospital stay and limb loss. Further detailed studies are required to 
produce repeated significant results, which is essential for the scoring system to be 
applied as an established protocol.  
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INTRODUCTION 
Soft tissue skin infections (SSTI’s) were first described in the 
Hippocratic era. In time various surgeons described the disease process in 
details. The most well documented among these is the work of Joseph Jones 
a confederate army surgeon, who reported 2,642 cases of “hospital 
gangrene” with a mortality rate of 46%. Since then, multiple reports and 
classification systems have been published in an attempt to define this 
disease better and achieve lower mortality rates with better outcomes. The 
principles of management, including early diagnosis with prompt and 
repeated surgical debridement, aggressive resuscitation and physiological 
support, broad spectrum antimicrobial drugs, and nutritional support, have 
been well documented. Despite this well accepted management approach, 
the mortality rate remains between 16 – 34% in most major published series. 
Over the last decade, there has been an interest in understanding SSTIs 
better. Some investigators have focused on methods that aid in early 
diagnosis so that surgical debridement can be accomplished promptly, 
whereas other researchers have focused on identifying patients at higher risk 
of death. Although several predictors of death have been identified, 
differences in patients across series limit their broad applicability. 
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 Due to the lack of defined criteria to determine the type of treatment 
that has to be given for patients at the time of admission, most patients 
undergo multiple surgical procedures which increases the morbidity and 
mortality. The primary objective of this analysis is to create a simple clinical 
score to aid in the prediction of morbidity defined by the number of days of 
hospital stay or limb loss and mortality in patients with SSTIs at the time of 
first assessment. The scoring system may further be used to predict limb loss 
at first assessment, thereby reducing multiple surgeries for the same patient. 
 
 
 
 
 
 
 
 
 
 
6 
 
AIMS OF THE STUDY 
The aims of the study is, 
1) To establish a scoring system to predict the outcome of a patient with 
non diabetic soft tissue limb infection at the time of admission. 
2) To determine the factors which increase the morbidity of a patient with 
non diabetic soft tissue limb infection as determined by no. Of days of 
hospital stay or limb loss or death of the patient. 
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REVIEW OF LITERATURE 
HISTORY 
Skin and soft tissue infections have been described since 5
th
 century 
BC. The first clear reference to necrotizing fasciitis (NF) dates back to the 
5th century BC, with Hippocrates’ description of a fatal infection, 
“Many were attacked by the erysipelas all over the body when the 
 exciting cause was a  trivial accident. The erysipelas would quickly spread 
widely in all directions. Flesh, sinews and bones fell away in large 
quantities…Fever was sometimes present and sometimes absent…There 
were many deaths. The course of the disease was the same to whatever part 
of the body it spread."
[1]
  
From the 18th and 19th century the British naval surgeons referred to 
the necrotizing fasciitis (NF) as "hospital gangrene."  Indeed the first modern 
report that describes a detailed case of "hospital gangrene" was reported by 
Joseph Jones, a Confederate Army Surgeon during the American Civil War. 
He was the first person to describe this disorder in a large group 
of patients. He reported 2,642 cases and found  
a mortality rate of 46%. 
[2]. 
Jean Alfred Fournier (1883) described a 
similar necrotizing soft tissue  infection of the perineum in five male  
8 
 
patients.
[3]
 The condition that bears  his name is now described in both 
male and female patients. 
  A major advance took place in 1924 when Meleney and Breuer 
isolated streptococcal infection as the prime cause of lethal NF
[4]
. Before the 
advent of the antibiotics, NF was treated successfully with "bear-claw 
scratch debridement" and tubes irrigating the tissues with Dakin's solution of 
chlorinated sofa
[5]
. In 1924, a Beijing missionary surgeon reported similar 
conditions among the opium addicts.
 
Over the years, many terms have been developed and used such as 
flesh-eating bacteria syndrome, suppurative fasciitis, and streptococcal 
gangrene."Meleney's gangrene" is commonly used for abdominal fasciitis, 
but strictly speaking should be streptococcal dermal gangrene on any part of 
body. The term "necrotizing fasciitis" was coined by Wilson in 1952, to 
delineate the histological appearance of the disease, that is, an invasive 
necrotizing infection involving deep fascia and soft tissue. 
[6] 
From 1987 to 1990, scattered outbreaks of NF were reported in both 
the USA and Scandinavia, while significant media attention focused on a 
close cluster of NF cases in West Gloucestershire in 1994
[7]
. In 1995 a small 
number of cases were reported in Canada and California. 
[8]
 Nowak suggests 
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there has been an increase in the incidence of severe streptococcal infection 
throughout the 20
th
 century, resulting in more cases of NF being identified 
and treated.
[9]
 While most Westernised countries are said to have an incident 
rate of around one in every 100,000 people, the latest Indian statistics 
suggests an incidence of 4 in every 100,000 people.
[10] 
Recently, the term necrotizing soft tissue infection 
has been adopted.
[11] 
DEFINITION 
Skin and soft tissue infections (SSTI) are classified into complicated 
and uncomplicated infections.
[11]
 Uncomplicated SSTI’s include cellulitis, 
erysipelas, simple abscesses,impetigo, ecythyma, follicilitis, furunculosis 
and carbuncles. They are superficial infections and have a low mortality and 
morbidity (limb loss). They can be treated by antibiotic therapy and drainage 
procedures. 
Complicated SSTI’s includes necrotizing soft tissue 
infections, complicated abscesses, infected burn wound, infected ulcers,  
infections with significant underlying disease states that complicates  
response to treatment (e.g. DM). These are usually deeper infections with 
higher mortality and morbidity, (i.e.) a higher chance of limb loss.
[12] 
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Necrotizing soft tissue infections by definition include the presence of 
necrotic or devitalized tissue as part of the pathophysiology
[13]
.Necrotic  
tissue provides a growth medium for bacteria and precludes delivery  
of host defence mechanisms and antimicrobial agents
[13]
. Necrotizing soft 
tissue infections includes, necrotizing cellulitis (involvement of dermal and 
subcutaneous layers), necrotizing fasciitis (involvement of deep fascia) and 
pyomyositis or myonecrosis or a combination of any of the above.
[14] 
PATHOPHYSIOLOGY 
Necrotizing fasciitis is characterized by widespread necrosis of the 
subcutaneous tissue and the fascia. Although the pathogenesis of necrotizing 
fasciitis is still open to speculation, the rapid and destructive clinical course 
of necrotizing fasciitis is thought to be due to multibacterial symbiosis and 
synergy.
[15]
Historically, group A beta-haemolytic Streptococcus (GABS) has 
been identified as a major cause of this infection. This monomicrobial 
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infection is usually associated with an underlying cause, such as 
diabetes,
[16] 
atherosclerotic vascular disease, or venous insufficiency with 
oedema. GABS usually affects the extremities; approximately two thirds of 
the GABS infections are located in the lower extremities.
[17]
 
During the last 2 decades, researchers have found that necrotizing 
fasciitis is usually polymicrobial rather than monomicrobial.
[18, 19, 
20] 
Anaerobic bacteria are present in most necrotizing soft-tissue infections, 
usually in combination with aerobic gram-negative organisms. Anaerobic 
organisms proliferate in an environment of local tissue hypoxia in those 
patients with trauma, recent surgery, or medical compromise. Facultative 
aerobic organisms grow because polymorphonuclear neutrophils (PMNs) 
exhibit decreased function under hypoxic wound conditions. This growth 
further lowers the oxidation/reduction potential, enabling more anaerobic 
proliferation and, thus, accelerating the disease process. Carbon dioxide and 
water are the end products of aerobic metabolism. Hydrogen, nitrogen, 
hydrogen sulphide, and methane are produced from the combination of 
aerobic and anaerobic bacteria in a soft tissue infection. These gases, except 
carbon dioxide, accumulate in tissues because of reduced water solubility. In 
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necrotizing fasciitis, group A haemolytic streptococci and Staphylococcus 
aureus, alone or in synergism, are frequently the initiating infecting bacteria.  
However, other aerobic and anaerobic pathogens may be present, including 
the following: 
 Bacteroides 
 Clostridium 
 Peptostreptococcus 
 Enterobacteriaceae 
 Coliforms (eg, Escherichia coli) 
 Proteus 
 Pseudomonas 
 Klebsiella 
Bacteroides fragilis is usually noted as part of a mixed flora in 
combination with E coli. B fragilis does not directly cause these infections, 
but it does play a part in reducing interferon production and the phagocytic 
capacity of macrophages and PMNs. 
A variant synergistic necrotizing cellulitis is considered to be a form of 
necrotizing fasciitis, but some authorities feel that it is actually a 
nonclostridial myonecrosis. This condition begins in the same manner as 
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necrotizing fasciitis, but it progresses rapidly to involve wide areas of deeper 
tissue and muscle at an earlier stage than might be expected. Severe systemic 
toxicity occurs. 
Anaerobic streptococci, occasionally seen in intravenous drug users, 
cause many forms of nonclostridial myonecrosis. Some cases of necrotizing 
fasciitis can be caused by Vibrio vulnificus. This organism is seen more 
often in patients with chronic liver dysfunction, and it often follows the 
consumption of raw seafood. V vulnificus may cause subcutaneous 
bleeding.
[23,24] 
Organisms spread from the subcutaneous tissue along the superficial 
and deep fascial planes, presumably facilitated by bacterial enzymes and 
toxins. This deep infection causes vascular occlusion, ischemia, and tissue 
necrosis. Superficial nerves are damaged, producing the characteristic 
localized anaesthesia. Septicaemia ensues with systemic toxicity. 
A subset of virulence factors, for instance, SpeB and Ska/ Plasmin 
directly damage the host tissues, degrade the extracellular matrix proteins, 
and induce vascular dissemination via their enzymatic pathway
[26]
. Other 
virulence factors such as SpyCEP and Mac1/IdeS indirectly damage the host 
tissue by cleaving immune molecules, inactivate PMN and stimulate release 
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of proapoptotic molecules. Host matrix metalloproteninases (MMPs) and 
coagulopathy are also implicated. 
 
Important bacterial factors include surface protein expression and toxin 
production. M-1 and M-3 surface proteins, which increase the adherence of 
the streptococci to the tissues, also protect the bacteria against phagocytosis 
by neutrophils. 
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Organisms undergo a very complex molecular transition during the 
progression from a localized to an invasive infection. SpeB, a broad-
spectrum cysteine protease virulence factor, is regulated by multiple 
intersecting and collateral pathways that respond to different environmental 
stimuli. SpeB is repressed, activated and regulated by multiple regulatory 
pathways. The combined effects result an in vivo temporal-spatial 
expression pattern of SpeB. 
  
Streptococcal pyrogenic exotoxins
[27]
 (SPEs) A, B, and C are directly 
toxic and tend to be produced by strains causing necrotizing fasciitis. These 
pyrogenic exotoxins, together with streptococcal superantigen (SSA), lead to 
the release of cytokines and produce clinical signs such as hypotension. The 
etiological agent may also be a Staphylococcus aureus isolate harbouring the 
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enterotoxin gene cluster seg, sei, sem, sen, and seo, but lacking all common 
toxin genes, including Panton-Valentine leukocidin.
[28]
 
The poor prognosis associated with necrotizing fasciitis has been 
linked to infection with certain streptococcal strains. Community-acquired 
methicillin-resistant S aureus (MRSA) has also been associated with 
necrotizing fasciitis.
[29]
 
Single-nucleotide changes are the most common cause of natural 
genetic variation among members of the same species. They may alter 
bacterial virulence; a single-nucleotide mutation in the group 
A Streptococcus genome was identified that is epidemiologically associated 
with decreased human necrotizing fasciitis.
[30]
 
It was found that wild-type mtsR function is required for group 
A Streptococcus to cause necrotizing fasciitis in mice and nonhuman 
primates. It was speculated that a naturally occurring single-nucleotide 
mutation dramatically alters virulence by dysregulating a multiple gene 
virulence axis. 
Severe myositis accompanying septic necrotizing fasciitis may be 
caused by a Panton-Valentine leukocidin–positive S 
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aureus strain.
[31] 
Immunostaining may document strong binding of the 
Panton-Valentine leukocidin toxin to necrotic muscle tissues. 
Although necrotizing fasciitis most frequently develops after trauma 
that compromises skin integrity, it may rarely develop in a healthy person 
after minor trauma such as an isolated shoulder sprain that occurred without 
a break in skin barrier.
[32]
 
ETIOLOGY 
Surgical procedures may cause local tissue injury and bacterial 
invasion, resulting in necrotizing fasciitis. These procedures include surgery 
for intraperitoneal infections and drainage of ischiorectal and perianal 
abscesses. Intramuscular injections and intravenous infusions may lead to 
necrotizing fasciitis. 
Minor insect bites may set the stage for necrotizing infections. 
Streptococci introduced into the wounds may be prominent initially, but the 
bacteriologic pattern changes with hypoxia-induced proliferation of 
anaerobes. 
Local ischemia and hypoxia can occur in patients with systemic 
illnesses (eg, diabetes). Host defences can be compromised by underlying 
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systemic diseases favouring the development of these infections. Illnesses 
such as diabetes or cancer have been described in over 90% of cases of 
progressive bacterial gangrene. 
Of patients with necrotizing fasciitis, 20-40% are diabetic. As many as 
80% of Fournier gangrene cases occur in people with diabetes. In some 
series, as many as 35% of patients were alcoholics. However, approximately 
one half of the cases of streptococcal necrotizing fasciitis occur in young and 
previously healthy people. 
Studies have shown a possible relationship between the use of 
nonsteroidal anti-inflammatory agents (NSAIDs), such as ibuprofen, and the 
development of necrotizing fasciitis during varicella infections. Additional 
studies are needed to establish whether ibuprofen use has a causal role in the 
development of necrotizing fasciitis and its complications during varicella 
infections. This has not previously been described. 
Group A beta-haemolytic streptococci have historically been noted as a 
cause of necrotizing fasciitis, but Haemophilus aphrophilus and S aureus are 
also associated with the condition, and some patients have mixed infections 
involving multiple species of bacteria, including mycobacteria, as well as 
fungi.
[33, 34]
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A synergistic infection with a facultative anaerobic bacterium may be 
significant. In 1 patient, Phycomycetes appeared to be responsible for 
necrotizing fasciitis. 
Streptococcus pneumoniae is a rare cause of necrotizing fasciitis.
[33] 
In 
one patient, S pneumoniae serotype 5 was also isolated. This serotype 5 
antigen is included in the polysaccharide 23-valent pneumococcal vaccine, 
highlighting the value of pneumococcal immunization. 
In type I necrotizing fasciitis
[21]
, anaerobic and facultative bacteria 
work synergistically to cause what may initially be mistaken for a simple 
wound cellulitis. A variant of type I necrotizing fasciitis is saltwater 
necrotizing fasciitis in which an apparently minor skin wound is 
contaminated with saltwater containing a Vibrio species. 
In type II necrotizing fasciitis,
[22]
 varicella infection and the use of 
nonsteroidal anti-inflammatory drugs may be predisposing factors. 
Type III necrotizing fasciitis is usually caused by Clostridium 
perfringens
[25]
. When type III necrotizing fasciitis occurs spontaneously, C 
septicum is more likely to be the etiologic agent; these cases usually occur in 
association with colon cancer or leukaemia. 
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Unusual causes include injection anthrax.
[35] 
Rapidly progressive 
necrotizing fasciitis following a stonefish sting has been described in 2 
patients.
[36]
 
PREDISPOSING OR RISK FACTORS FOR NECROTIZING 
FASCIITIS
[37,38] 
 
PROGNOSIS 
The reported mortality in patients with necrotizing fasciitis has ranged 
from 20% to as high as 80%.
[25, 27, 39] 
Pathogens, patient characteristics, 
infection site, and speed of treatment are among the variables that affect 
survival. 
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Poor prognosis in necrotizing fasciitis has been linked to infection with 
certain streptococcal strains. However, McHenry et al found that 
monomicrobial infection with S pyogenes was not associated with an 
increased mortality.
[27]
 
A retrospective study by Hsiao et al found 
that Aeromonas infection, Vibrio infection, cancer, hypotension, and band 
form WBC count greater than 10% were independent positive predictors of 
mortality in patients with necrotizing fasciitis, while streptococcal and 
staphylococcal infections were not identified as predictors of mortality. 
Hemorrhagic bullae appeared to be an independent negative predictor of 
mortality. However, accuracy of these factors needs to be verified.
[40] 
 
In another study, pre-existing chronic liver dysfunction, chronic renal 
failure, thrombocytopenia, hypoalbuminemia, and postoperative dependence 
on mechanical ventilation represented poor prognostic factors in 
monomicrobial necrotizing fasciitis. In addition, patients with gram-negative 
monobacterial necrotizing fasciitis had more fulminant sepsis.
[41]
 
The mean age of survivors is 35 years. The mean age of non survivors 
is 49 years. 
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A retrospective review by Cheng et al showed that upper extremity 
necrotizing fasciitis has a high mortality rate. In their review, about 35% of 
patients died. A state of altered consciousness and respiratory distress at 
initial presentation were found to be statistically significant factors for 
eventual mortality. Early diagnosis and referral for aggressive surgical 
treatment prior to the development of systemic toxic signs are essential for 
survival.
[42]
 
In a retrospective review of craniocervical necrotizing fasciitis, Mao et 
al reported a survival rate of 60% for patients with thoracic extension (6 of 
10) compared with 100% for those without thoracic extension. Lower 
overall survival for the patients in the thoracic extension group was 
attributed to older patient age, greater co morbidity, need for more extensive 
surgical debridement, and increased postoperative complications. 
Better survival of the patients without thoracic extension was attributed 
to aggressive wound care and surgical debridement, broad-spectrum 
intravenous antibiotics, and care in the surgical intensive care unit.
[43]
 
In a study by Rouse et al, the overall mortality rate was 73% (20 of 27 
patients). They indicated that prompt recognition and treatment of 
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necrotizing fasciitis was essential: Of 12 patients whose treatment was 
delayed for more than 12 hours, 11 patients died.
[25]
 
Similarly, McHenry et al reported that the average time from 
admission to operation was 90 hours in nonsurvivors of necrotizing soft-
tissue infections; in survivors, this average time was 25 hours.
[27] 
Early 
debridement of the infection was obviously associated with a significant 
decrease in mortality. 
Necrotizing fasciitis survivors may have a shorter life span than 
population controls, owing to infectious causes such as pneumonia, 
cholecystitis, urinary tract infections, and sepsis.
[44]
 
COMMON SITES OF INFECTION 
While any area of the body can succumb to NF, the most common sites 
are the extremities, the abdominal wall, the perianal and groin area and post-
operative wounds.
 
CLINICAL PRESENTATION 
Diagnosis of necrotizing fasciitis can be difficult and requires a high 
degree of suspicion. In many cases of necrotizing fasciitis, antecedent 
trauma or surgery can be identified. Surprisingly, the initial lesion is often 
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trivial, such as an insect bite, minor abrasion, boil, or injection site. 
Idiopathic cases are not uncommon, however. 
Olafsson et al indicate that the hallmark symptom of necrotizing 
fasciitis is intense pain and tenderness over the involved skin and underlying 
muscle.
[45] 
The intensity of the pain often causes suspicion of a torn or 
ruptured muscle. This severe pain is frequently present before the patient 
develops fever, malaise, and myalgias. 
In some cases, the symptoms may begin at a site distant from the initial 
traumatic insult. Pain may be out of proportion to physical findings. Over the 
next several hours to days, the local pain progresses to anaesthesia. 
Other indicative findings include oedema extending beyond the area of 
erythema, skin vesicles, and crepitus. McHenry et al and others have noted 
that the subcutaneous tissue demonstrates a wooden, hardened feel in cases 
of necrotizing fasciitis.
[26] 
The fascial planes and muscle groups cannot be 
detected by palpation. 
A history of co morbid factors, including diabetes mellitus, should be 
sought in all cases of suspected necrotizing fasciitis. 
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Physical findings may not be commensurate with the degree of patient 
discomfort. Early in the disease course, the patient may look deceptively 
well; unfortunately, this may interfere with early detection, which is key to a 
favourable outcome. Soon, however, the patient will usually begin to appear 
moderately to severely toxic. 
Typically, the infection begins with an area of erythema that quickly 
spreads over a course of hours to days. The redness quickly spreads, and its 
margins move out into normal skin without being raised or sharply 
demarcated. As the infection progresses, the skin near the site of insult 
develops a dusky or purplish discoloration. Multiple identical patches 
expand to produce a large area of gangrenous skin, as the erythema 
continues to spread. 
Iwata et al reported that 2 of 3 patients who lacked inflammatory signs 
such as redness and heat experienced fulminant progression of necrotizing 
fasciitis and death.
[46]
 
The initial necrosis appears as a massive undermining of the skin and 
subcutaneous layer. If the skin is open, gloved fingers can pass easily 
between the 2 layers and may reveal yellowish-green necrotic fascia. If the 
skin is unbroken, a scalpel incision will reveal it. 
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The normal skin and subcutaneous tissue become loosened from the 
rapidly spreading deeper necrotic fascia that is a great distance from the 
initiating wound. Fascial necrosis is typically more advanced than the 
appearance suggests. 
Anaesthesia in the involved region may be detected, and it usually is 
caused by thrombosis of the subcutaneous blood vessels, leading to necrosis 
of nerve fibres. Without treatment, secondary involvement of deeper muscle 
layers may occur, resulting in myositis or myonecrosis. Normally, however, 
the muscular layer remains healthy red with normal bleeding muscle under 
the yellowish-green fascia. 
Usually, the most important signs are tissue necrosis, putrid discharge, 
bullae, severe pain, gas production, rapid burrowing through fascial planes, 
and lack of classical tissue inflammatory signs. 
Usually, some degree of intravascular volume loss is detectable on 
clinical examination. Other general signs, such as fever and severe systemic 
reactions, may be present. Local crepitation can occur in more than one half 
of patients. This is an infrequent finding, specific but not sensitive, 
particularly in cases of nonclostridial necrotizing fasciitis. 
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At this point the patient is grossly unwell, experiencing shock, reduced 
perfusion, fluid and electrolyte disturbances and an altered mental state. 
Death from disseminated intravascular coagulation and multi-organ system 
failure can occur in at least 30 per cent of cases.
[1,8,47,48] 
PHYSICAL FINDINGS OF CLINICAL FEATURES
[49] 
FINDINGS PERCENTAGE 
PAIN 100 
ERYTHEMA 95 
OEDEMA 82 
CELLULITIS 75 
FEVER 70 
DISCOLOURATION 49 
CREPITATION 25 
VESICLES 16 
 
Fournier gangrene in males begins with local tenderness, itching, 
oedema, and erythema of the scrotal skin. This progresses to necrosis of the 
scrotal fascia. The scrotum enlarges to several times its normal diameter. If 
the process continues beyond the penile-scrotal region to the abdomen or the 
upper legs, the normal picture of necrotizing fasciitis can be seen. 
In males, the scrotal subcutaneous layer is so thin that most patients 
present after the skin is already exhibiting signs of necrosis. In 2-7 days, the 
skin becomes necrotic, and a characteristic black spot can be seen. Early on, 
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this infection may resemble acute orchitis, epididymitis, torsion, or even a 
strangulated hernia. 
In women, Fournier gangrene acts more like necrotizing fasciitis 
because of the thicker subcutaneous layers involving the labia majora and 
the perineum. 
Complications may include the following: 
 Renal failure 
 Septic shock with cardiovascular collapse 
 Scarring with cosmetic deformity 
 Limb loss 
 Sepsis 
 Toxic shock syndrome 
Metastatic cutaneous plaques may occur in necrotizing fasciitis. 
Septicaemia is typical and leads to severe systemic toxicity and rapid death 
unless appropriately treated. 
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CLINICAL STAGES OF NECROTIZING FASCIITIS
[55] 
STAGE FEATURES 
1- EARLY Tenderness  beyond  skin involvement 
Erythema  
Swelling  
Calor  
2- INTERMEDIATE Blisters or bullae formation 
3- LATE Crepitus 
Skin anaesthesia 
Skin necrosis 
 
INVESTIGATIONS 
Laboratory tests, along with appropriate imaging studies, may facilitate 
the diagnosis of necrotizing fasciitis.
[50] 
Laboratory evaluation should 
include the following: 
 Complete blood count with differential 
 Serum chemistry studies 
 Arterial blood gas measurement 
 Urinalysis 
 Blood and tissue cultures 
30 
 
Skin and superficial tissue cultures may be inaccurate because samples 
may not contain the infected tissue. Deeper tissue samples, obtained at the 
time of surgical debridement, are needed to obtain proper cultures for 
microorganisms. New techniques include rapid streptococcal diagnostic kits 
and a polymerase chain reaction (PCR) assay for tissue specimens that tests 
for the genes for streptococcal pyrogenic exotoxin (SPE; eg, SPE-B) 
produced by group A streptococci. B-mode and possibly colour Doppler 
ultrasonography, contrast-enhanced computed tomography (CT) scanning, or 
magnetic resonance imaging (MRI) can promote early diagnosis of 
necrotizing infections.
[51] 
In addition, these studies permit visualization of 
the location of the rapidly spreading infection. More importantly, MRI or CT 
scan delineation of the extent of necrotizing fasciitis may be useful in 
directing rapid surgical debridement. However, when the patient is seriously 
ill, necrotizing fasciitis is a surgical emergency with high mortality. 
Therefore, laboratory tests and imaging studies should not delay surgical 
intervention.
[52]
 
Most fluid collections in the tissue, especially in the musculoskeletal 
system, can be localized and aspirated under ultrasonographic guidance. 
Whether fluid is infected cannot be determined on the basis of its 
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ultrasonographic characteristics; however, laboratory analysis of the 
aspirated fluid can help in identifying the pathogen.
[53]
 
In a study of 13 patients with thoracic and abdominal wall infections, 
Sharif et al reported that CT and MRI were superior to sonography, 
scintigraphy, and plain radiography in providing useful information about 
the nature and extent of infections.
[54] 
Furthermore, they point out that while 
CT compares favourably with MRI in accurate diagnosis of soft tissue 
infection, multiplanar MRI images can be obtained without ionizing 
radiation and the use of intravenous contrast agents. 
Although the laboratory results may vary in a given clinical setting, the 
following may be associated with necrotizing fasciitis: 
 Elevated white blood cell (WBC count), possibly to more than 14,000/µL 
 Elevated blood urea nitrogen (BUN) level, possibly to greater than 15 
mg/mL 
 Reduced serum sodium level, possibly to less than 135 mmol/L 
SCORING SYSTEMS 
A numerical score sheet, called the laboratory risk indicator for 
necrotizing fasciitis (LRINEC), was devised from lab parameters as a 
possible indicating tool for detection of necrotizing fasciitis. Score of ≥6 
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has a positive predictive value of 92% and a negative predictive value of 
96%. 
[56] 
 
 
IMAGING STUDIES 
Radiographs 
Plain radiographs, often obtained to detect soft-tissue gas that is 
sometimes present in polymicrobial or clostridial necrotizing fasciitis, are of 
no value in the diagnosis of necrotizing infections.
[57] 
Indeed, nondiagnostic 
plain radiographs may even hinder the diagnosis of necrotizing 
infection.
[51] 
In their study of 29 patients with necrotizing soft tissue 
infections, Lille et al reported that nondiagnostic radiographs correlate with a 
33 
 
delay in operative intervention and consequent increased morbidity and 
mortality.
[58]
 
The presence of subcutaneous gas in a radiograph does not necessarily 
indicate a clostridial infection, as Escherichia coli, 
Peptostreptococcus species, and Bacteroides species may produce gas under 
appropriate conditions. Misleading subcutaneous gas can also result from the 
undermining of tissue planes during surgical debridement. Perforations of 
the oesophagus, the respiratory tract, or the GI tract related to endoscopy or 
chest tube insertion can result in the radiographic appearance of gas. 
Ultrasonography 
Bedside ultrasonography may be useful in patients with necrotizing 
fasciitis, as well as other soft-tissue infections including cellulitis, cutaneous 
abscess, and peritonsillar abscess. It may be superior to clinical judgment 
alone in determining the presence or the absence of occult abscess 
formation.
[59]
 
Sonography may reveal subcutaneous emphysema spreading along the 
deep fascia, swelling, and increased echogenicity of the overlying fatty 
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tissue with interlacing fluid collections, allowing for early surgical 
debridement and parenteral antibiotics.
[60]
 
Parenti et al retrospectively reviewed the ultrasonographic appearances 
of 32 pathologically proven cases of necrotizing fasciitis.
[51] 
Ultrasonography 
revealed changes in the subcutaneous fat (28 of 32 patients), investing fascia 
(18 of 32 patients), and muscle (15 of 32 patients), which correlated well 
with histological findings. However, in some cases, ultrasonography missed 
histologically apparent inflammation in the subcutaneous tissues (3 of 32 
patients) or muscle (8 of 32 patients).
[61]
 
CT and MRI 
CT scanning can pinpoint the anatomic site of involvement by 
demonstrating necrosis with asymmetric fascial thickening and the presence 
of gas in the tissues. However, note that early on, CT findings may be 
minimal.  
While no published, well-controlled, clinical trial has compared the 
efficacy of various diagnostic imaging modalities in the diagnosis of 
necrotizing infections, MRI is the preferred technique to detect soft tissue 
infection because of its unsurpassed soft-tissue contrast and sensitivity in 
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detecting soft-tissue fluid, its spatial resolution, and its multiplanar 
capabilities.
[62, 63]
 
The usefulness of MRI in the diagnosis of necrotizing fasciitis has been 
supported in a study by Rahmouni et al, who were able to differentiate 
nonnecrotizing cellulitis that would respond to medical treatment from 
severe necrotizing infections that required rapid life-saving surgery.
[64] 
In 
necrotizing fasciitis, MRI can provide dramatic evidence of an inflammatory 
process infiltrating the fascial planes.
[51]
 
Craig notes that the combined use of MRI and aspiration under 
ultrasonographic guidance is very useful in complicated infections (eg, 
septic arthritis and osteomyelitis) and that its role in the diagnosis of 
necrotizing fasciitis should be considered.
[65] 
Early muscle necrosis may be 
apparent.  
Absence of gadolinium contrast enhancement in T1 images reliably 
detects fascial necrosis in those requiring operative debridement. Combined 
with clinical assessment, MRI can determine the presence of necrosis and 
the need for surgical debridement. T2-weighted MRI may show well-defined 
regions of high signal intensity in the deep tissues. However, the sensitivity 
of MRI exceeds its specificity.
[66]
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OTHER TESTS 
Finger Test and Biopsy 
The finger test should be used in the diagnosis of patients who present 
with necrotizing fasciitis.
[67, 68] 
The area of suspected involvement is first 
infiltrated with local. A 2-cm incision is made in the skin down to the deep 
fascia. Lack of bleeding is a sign of necrotizing fasciitis. On some occasions, 
a dishwater-colored fluid is noticed seeping from the wound. 
A gentle, probing manoeuvre with the index finger covered by a sterile 
powder-free surgical double glove puncture indication system is then 
performed at the level of the deep fascia. If the tissues dissect with minimal 
resistance, the finger test is positive. 
Tissue biopsies are then sent for frozen section analysis. The 
characteristic histologic findings are obliterative vasculitis of the 
subcutaneous vessels, acute inflammation, and subcutaneous tissue necrosis. 
If either the finger test or rapid frozen section analysis is positive, or if the 
patient has progressive clinical findings consistent with necrotizing fascia, 
immediate operative treatment must be initiated. 
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Excisional deep skin biopsy 
Excisional deep skin biopsy may be helpful in diagnosing and 
identifying the causative organisms.
[69] 
Specimens can be taken from the 
spreading periphery of the necrotizing infection or the deeper tissues, 
reached only in surgical debridement, to obtain proper cultures for 
microorganisms. 
This procedure is not done from the actual necrosis or granulating 
centre, as many bacteria that neither cause nor add to the infection would be 
detected. 
ASPIRATION AND GRAM STAIN 
Uman et al recommended percutaneous needle aspiration followed by 
prompt Gram staining and culture for a rapid bacteriologic diagnosis in soft-
tissue infections.
[70] 
A needle aspirate should be taken on the advancing edge 
of the infection, where group A beta-haemolytic Streptococcus (GABS) is 
plentiful.
[71]
 
The Gram stain usually shows a polymicrobial flora with aerobic 
gram-negative rods and positive cocci when polymicrobial infection is 
present. However, in many cases, a single organism (eg, GABS, methicillin-
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resistant Staphylococcus aureus[MRSA], Clostridium) may be causing the 
infection, while cultures, including blood cultures, may spuriously reveal a 
polymicrobial infection. The presence of plentiful cocci on the Gram stain is 
characteristic of necrotizing infection, whereas cocci are rarely identified 
in erysipelas.
[71]
 
Polymicrobial infections are often associated with previous surgical 
procedures, pressure ulcers, penetrating trauma, perianal abscesses, and 
intravenous drug use. In the study by Andreasen et al, 71% of their patients 
had polymicrobial infections.
[19]
 
Histologic Findings 
Sections from necrotizing fasciitis tissue show superficial fascial 
necrosis with blood vessels occluded by thrombi. A dense infiltration of 
neutrophils may be observed in deeper parts of the subcutaneous tissue and 
fascia. Subcutaneous fat necrosis and vasculitis are also evident. Eccrine 
glands and ducts may be necrotic. Alcian blue or periodic acid-Schiff 
staining with diastase may show clusters of bacteria and fungi (see the image 
below). 
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TREATMENT AND MANAGEMENT 
Approach Considerations 
Once the diagnosis of necrotizing fasciitis is confirmed, treatment 
should be initiated without delay. Because of the complexity of this disease, 
a team approach is best. Hemodynamic parameters should be closely 
monitored, and aggressive resuscitation initiated immediately if needed to 
maintain hemodynamic stability. 
Because necrotizing fasciitis is a surgical emergency, the patient 
should be admitted immediately to a surgical intensive care unit in a setting 
such as a regional burn centre or trauma centre, where the surgical staff is 
skilled in performing extensive debridement and reconstructive surgery. 
Such regional burn centres are ideal for the care of these patients because 
they also have hyperbaric oxygen facilities. 
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A regimen of surgical debridement is continued until tissue necrosis 
ceases and the growth of fresh viable tissue is observed. If a limb or organ is 
involved, amputation may be necessary because of irreversible necrosis and 
gangrene or because of overwhelming toxicity, which occasionally occurs. 
Prompt surgery ensures a higher likelihood of survival. 
Antibiotic therapy is a key consideration. Possible regimens include a 
combination of penicillin G and an amino glycoside (if renal function 
permits), as well as clindamycin (to cover streptococci, staphylococci, gram-
negative bacilli, and anaerobes). 
While the literature appears to support the use of hyperbaric oxygen as 
an adjunctive treatment measure in patients with necrotizing fasciitis. 
However, transfer to a hospital equipped with a hyperbaric oxygen chamber 
should not delay emergency surgical intervention. 
Surgical Debridement 
Surgery is the primary treatment for necrotizing fasciitis. .Surgeons 
must be consulted early in the care of these patients, as early and aggressive 
surgical debridement of necrotic tissue can be life-saving.
[4, 58, 72, 73, 74] 
In 
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addition, early surgical treatment may minimize tissue loss, eliminating the 
need for amputation of the infected extremity.
[75,76]
 
It is recommended to do a wide, extensive debridement of all tissues 
that can be easily elevated off the fascia with gentle pressure. Wide 
debridement of all necrotic and poorly perfused tissues is associated with 
more rapid clinical improvement. 
Controversy exists regarding how much tissue should be initially 
excised because the skin may often appear normal. Andreasen et al 
examined the normal-appearing tissues microscopically and reported that the 
tissues had extensive early vascular thrombosis as well as vasculitis.
[19] 
Their 
findings indicate that these tissues, though they have a normal appearance, 
have a high potential for full-thickness loss. 
After the initial debridement, the wound must be carefully examined. 
Hemodynamic instability is usually present after surgery, and it may cause 
progressive skin necrosis. After debridement, the patient may return as often 
as necessary for further surgical debridement. The anaesthesiologist is an 
important member of the operative team because continued resuscitative 
efforts are undertaken during the operative procedure. 
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The surgical regimen can be summarized as follows: 
 Surgical incisions should be deep and extend beyond the areas of necrosis 
until viable tissue is reached 
 The entire necrotic area should be excised 
 The wound should be well irrigated 
 Haemostasis should be maintained, and the wound should be kept open 
 Surgical debridement and evaluations should be repeated almost on a daily 
basis 
 The wound should be inspected in the operating room 
Dressings 
Following each debridement of the necrotic tissue, daily antibiotic 
dressings are recommended.
[77] 
Silver sulfadiazine (Silvadene) remains the 
most popular antimicrobial cream. This agent has broad-spectrum 
antibacterial activity and is associated with relatively few complications in 
these wounds. 
The current formulation of silver sulfadiazine contains a lipid-soluble 
carrier, polypropylene glycol, which has certain disadvantages, including 
pseudoeschar formation. When this antibacterial agent is formulated with 
poloxamer 188, the silver sulfadiazine can be washed easily from the wound 
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because of its water solubility, making dressing changes considerably more 
comfortable. 
If the patient is allergic to sulpha, alternative agents include 
Polysporin, Bacitracin, and Bactroban. While these agents are relatively 
inexpensive, they may induce allergies. 
Mafenide is an alternate agent that penetrates eschar more effectively 
than silver sulfadiazine. Consequently, it is frequently used on infected 
wounds that do not respond to silver sulfadiazine. Use mafenide with caution 
because it can induce metabolic acidosis. 
Barrier dressings provide the beneficial antimicrobial properties of the 
silver ion by coating the dressing material with a thin, soluble silver film. 
This dressing appears to maintain antibacterial levels of silver ions in the 
wound for up to 5 days. Because these can remain on the wound for up to 5 
days, the patient is spared the pain and expense associated with the dressing 
changes. Additional studies are now under way to determine the ultimate 
benefit of this product. 
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Soft-tissue reconstruction 
Once all of the affected tissues have been debrided, soft tissue 
reconstruction can be considered. According to literature, this may take at 
least 2 debridements. When the debridement involves relatively small (< 
25%) body surface areas, skin grafts and flaps can provide coverage. When 
donor-site availability is limited, alternatives to standard skin graft 
construction must be considered, including Integra artificial skin (Integra 
Life Sciences, Plainsboro, NJ) and AlloDerm (LifeCell Corporation, 
Blanchburg, NJ).
[78, 79]
 
Antimicrobial Therapy 
Empiric antibiotics should be started immediately. Initial antimicrobial 
therapy should be broad-based, to cover aerobic gram-positive and gram-
negative organisms and anaerobes. A foul smell in the lesion strongly 
suggests the presence of anaerobic organisms. The maximum doses of the 
antibiotics should be used, with consideration of the patient's weight and 
liver and renal status. 
Antibiotic therapy is a key consideration. Possible regimens include a 
combination of penicillin G and an amino glycoside (if renal function 
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permits), as well as clindamycin (to cover streptococci, staphylococci, gram-
negative bacilli, and anaerobes). 
A more specifically targeted antibiotic regimen may be begun after the 
results of initial gram-stained smear, culture, and sensitivities are available. 
Although some necrotizing infections may still be susceptible to penicillin, 
clindamycin is the treatment of choice for necrotizing infections, for the 
following reasons
[57] 
: 
 Unlike penicillin, the efficacy of clindamycin is not affected by the 
inoculum size or stage of bacterial growth
[80,81]
 
 Clindamycin is a potent suppressor of bacterial toxin synthesis
[82, 83]
 
 Sub inhibitory concentrations of clindamycin facilitate the phagocytosis of 
GABS
[51]
 
 Clindamycin reduces the synthesis of penicillin-binding protein, which, in 
addition to being a target for penicillin, is also an enzyme involved in cell 
wall synthesis and degradation
[81]
 
 Clindamycin has a longer post antibiotic effect than β-lactams such as 
penicillin
[83]
 
 Clindamycin suppresses lipopolysaccharide-induced mononuclear synthesis 
of tumour necrosis factor-α (TNF-α)
[84]
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Consequently, the success of clindamycin also may be related to its ability to 
modulate the immune response.
[85]
 
Broad-spectrum beta-lactam drugs such as imipenem cover aerobes, 
including Pseudomonas species. Ampicillin sulbactam also has broad-
spectrum coverage, but it does not cover Pseudomonas species; however, 
necrotizing fasciitis caused by Pseudomonas aeruginosa is unusual.
[86]
 
If staphylococci or gram-negative rods are involved, vancomycin and 
other antibiotics to treat gram-negative organisms other than amino 
glycosides may be required. The use of vancomycin to treat methicillin-
resistant Staphylococcus aureus (MRSA) may depend on the clinical 
situation. For example, use may depend on whether a nasocranial infection is 
present, or it may need to be avoided in patients who are likely to be carriers 
of MRSA (eg, those with diabetes, those who use illicit drugs, those 
undergoing haemodialysis). 
Fluid, Nutritional Support, IVIG 
Because of persistent hypotension and diffuse capillary leak, massive 
amounts of intravenous fluids may be necessary after the patient is admitted 
to the hospital. Nutritional support is also an integral part of treatment for 
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patients with necrotizing fasciitis. This supplementation should be initiated 
as soon as hemodynamic stability is achieved. Enteral feeding should be 
established as soon as possible to offset the catabolism associated with large 
open wounds. 
Successful use of intravenous immunoglobulin (IVIG) has been 
reported in the treatment of streptococcal toxic shock syndrome (STSS).
[87, 
88] 
In a multicenter, randomized, double-blind, placebo-controlled trial of the 
efficacy and safety of high-dose polyspecific IVIG as adjunctive therapy in 
21 patients with soft-tissue STSS, mortality at 28 days was 3.6-fold higher in 
the placebo group.
[89]
 
Norrby-Teglund et al successfully used high-dose polyspecific IVIG, 
along with antimicrobials and a conservative surgical approach, in 7 patients 
with severe group A streptococcal soft tissue infections.
[90] 
However, Sarani 
et al indicate that this therapy has not been approved by the FDA for the 
treatment of necrotizing fasciitis.
[91]
 
Hyperbaric Oxygen Therapy 
Once other modalities, including surgical debridement and antibiotic 
administration, have been used, hyperbaric oxygen therapy (HBOT) may be 
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considered, if available.
[92, 40, 93] 
The literature suggests that HBOT can 
reduce mortality when used as part of an aggressive treatment regimen for 
necrotizing fasciitis.
[94, 45, 95, 49, 96]
 
Well-controlled, randomized, clinical trials demonstrating a 
statistically significant benefit of HBOT are lacking, however, and 
consequently its use as an adjunctive therapy for necrotizing fasciitis 
remains controversial.
[97, 98, 99] 
Transfer to a hospital equipped with HBOT 
should not delay emergency surgical intervention. 
RECENT CONTROVERSIES 
In the modern era, SSTIs were the focus of one of the first published 
clinical studies of an antibacterial agent
[100]
, as well as one of the first active-
controlled studies demonstrating the superiority of an antibacterial agent 
versus background medical therapy
[101]
. Given such a venerable and well-
documented history, perhaps it is surprising that SSTIs have become such a 
dynamic—even contentious—contemporary topic. 
Just in the last decade, the remarkable spread of methicillin-resistant 
Staphylococcus aureus (MRSA) as a cause of community-acquired 
infections has resulted in substantial changes in the epidemiology and 
treatment of SSTIs
[102-106]
. As a result, the frequency of health care visits and 
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antibacterial prescriptions for such infections has markedly increased
[107]
. 
Meanwhile, considerable controversy has arisen regarding the need to treat 
skin abscesses (including those caused by MRSA) with adjunctive 
antibacterial therapy, in addition to incision and drainage
[108,109]
. Such 
controversy has been exacerbated by the fact that most investigations 
exploring this issue have been highly underpowered and yet have still often 
shown trends toward a benefit of antibacterial therapy
[109]
. Furthermore, 
patients with complicated abscesses (eg, those accompanied by systemic 
signs of illness) have been excluded from such studies. 
Another recent controversy has developed regarding the precise 
magnitude of the therapeutic benefit of antibacterial therapy for other forms 
of SSTIs, such as cellulitis and wound/ulcer infections
[110,111]
 . This new 
controversy has resulted in a complete rethink of regulatory standards 
governing the conduct of clinical trials of new antibacterial agents for the 
treatment of complicated SSTIs. In the face of such dramatically changing 
clinical, scientific, and regulatory landscapes, new research in SSTIs is 
clearly needed to guide clinical practice, resolve scientific controversies, and 
create a framework for rational regulatory standards. 
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It is in this context that the importance of the study by Jenkins et al
[112]
 
that appears in this issue of Clinical Infectious Diseases should be 
appreciated. They systematically described the presentation, treatment, and 
outcomes of 322 cases of SSTIs at a comprehensive urban health care 
system in the United States during the year 2007. The high frequency of 
SSTIs seen during the year of study underscores the magnitude of the global 
societal problem. Furthermore, the authors described a general overuse of 
radiographic procedures (x-rays, computerized tomography, and magnetic 
resonance imaging scans) and laboratory testing (erythrocyte sedimentation 
rate and C-reactive protein) in patients with SSTIs. These tests resulted in 
very low diagnostic yields and thus likely substantially contributed to 
unnecessary health care expenditures related to SSTIs. 
Another factor affecting health care resources was selection of 
antimicrobial therapy. Appropriately, empiric treatment against MRSA was 
administered to most patients. Of great concern, however, is that a high 
percentage of patients received treatment with broad-spectrum antibacterial 
agents that had activity against gram-negative bacilli and anaerobes. Such 
patients also often received combinations of 3 or more antibacterial agents. 
The vast majority of intact-skin SSTIs (including cellulitis and abscess) are 
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caused by streptococci and staphylococci
[112,113]
. Treatment of infections 
caused by such a narrow spectrum of etiologic microbes with combinations 
of multiple agents, including those with broad activity against gram-negative 
bacilli and anaerobes, is antithetical to critically needed antibacterial 
stewardship. Hence, there is much work to be done to improve antibacterial 
prescribing behaviours for SSTIs. 
In previous years, cellulitis was considered by US Food and Drug 
Administration guidance to be indicative of an uncomplicated skin 
infection
[114]
. However, analysis of historical data has demonstrated that the 
mortality rate of cellulitis (or erysipelas as it was called before the 1950s) 
was ∼11% in the preantibiotic era, underscoring that cellulitis is a 
complicated infection that is made relatively benign only in the context of 
effective antibacterial therapy
[109]
. Furthermore, while historical data do 
demonstrate a substantial effect of antibacterial therapy for wound infections 
and carbuncles/major abscesses, much of the available data are from 
historically controlled studies or a systematic review of single-armed cohort 
studies
[109]
. Therefore, the US Food and Drug Administration will likely 
allow only patients with cellulitis to be considered evaluable for primary 
efficacy analysis in future antibacterial clinical trials of complicated SSTIs, 
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and patients with complicated abscesses or wound/ulcer infections, in the 
absence of concomitant cellulitis of 5 cm in diameter, are likely to be 
excluded from such studies
[110]
. However, Jenkins and colleagues classified 
only 20% of SSTIs as cellulitis. Some additional cases of cellulitis were 
probably classified as SSTIs with additional complicating factors because of 
the presence of other cofactors, such as health care contact, bacteraemia, and 
significant co morbidities. Nevertheless, the overall proportion of SSTIs 
identified as cellulitis was low, and the majority of patients seen had other 
skin infections. Therefore, insistence that only patients with cellulitis be 
enrolled in future clinical trials of SSTIs will make completion of enrolment 
of such studies very difficult and will leave clinicians in the unacceptable 
position of not knowing the efficacy of new antibacterial agents for 
complicated abscesses and wound and ulcer infections—regulatory thinking 
on this matter should be readdressed. 
The severity of the infections seen was also of crucial importance. For 
example, nearly 10% (10/103) of patients with abscesses as their SSTI 
manifestation were bacteraemia. This finding puts into sharp relief the 
debate regarding whether patients with cutaneous abscesses require 
adjunctive antibacterial therapy in addition to incision and drainage. 
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Adjunctive antibacterial therapy must not be withheld from patients who are 
potentially bacteraemia. Furthermore, the high rate of concomitant 
bacteraemia in patients with abscesses in the study by Jenkins and 
colleagues and the 6% mortality rate for complex abscesses in the 
preantibiotic era (which was largely due to sequelae from concomitant 
bacteraemia)
[109]
 underscore that these infections indeed can be 
“complicated.” Finally, the lack of mortality seen in the antibiotic era, 
including in the study by Jenkins and colleagues, underscores that 
antibacterial therapy is very effective in the treatment of complicated 
abscesses and that patients with these infections should be included in 
noninferiority studies of antibacterial therapy for SSTIs
[109]
. 
Limitations to the study by Jenkins and colleagues include the 
retrospective design, the lack of data capture on wound infections (resulting 
from the search criteria used), the commingling of severe SSTIs of several 
types within the broad category of SSTI with additional complicating 
factors, and the exclusion of paediatric data collection. Important 
information might have been gleaned by separately capturing data on 
cellulitis, wounds, ulcers, and abscesses and by analyzing these categories 
stratified by disease severity. Further study of SSTIs, including in children, 
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is greatly needed to advance clinical care, improve antibacterial stewardship, 
help reduce overuse of imaging and laboratory medical resources, and 
establish critical parameters in support of conduct of antibacterial clinical 
trials for these infections. Foci of study necessary to facilitate future 
antibacterial clinical trials include the following: quantification of the 
efficacy of active versus inactive antibacterial therapy for SSTI subtypes, 
establishment of a severity of illness scoring system for SSTIs, and 
identification of appropriate clinical end points for efficacy analysis. 
Skin infections have been around ever since the invention of skin, have 
been written about by Homo sapiens for >2500 years, and have been studied 
in the context of antibacterial therapy since the discovery of antibacterial 
therapy. But these infections are ever evolving, and our understanding must 
evolve with them to facilitate optimal clinical care and rational investigation 
and use of antibacterial therapy for SSTIs. 
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PATIENTS AND METHODS 
  My study was conducted in the Department of general surgery, 
Rajiv Gandhi Government General hospital, Chennai for a period of 18 
months from April 2012 to October 2013. 
  My study was to establish a scoring system to predict the 
outcome of a patient with non diabetic soft tissue infection of the lower 
limbs at admission using a multivariate analysis. My study also aims to 
determine the factors which increase the morbidity of a patient with a non 
diabetic soft tissue infection as determined by the no. Of days of hospital 
stay or limb loss or death of the patient. 
Two hundred cases of non diabetic soft tissue infections of the lower 
limb were studied retrospectively and analysed statistically to determine the 
factors that altered the outcome. This analysis was then used to establish a 
scoring system which was then applied on fifty cases of non diabetic patients 
with soft tissue infections of lower limb at the time of their hospital 
admission to determine the mode of management.  
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SELECTION OF SUBJECT 
All patients with soft tissue infections of the lower limbs including 
cellulitis, abscesses, necrotising fasciitis who were admitted to Rajiv Gandhi 
Govt. General Hospital during the study period were included. 
EXCLUSION CRITERIA 
Patients who were diabetics, either known cases or newly diagnosed 
were excluded from the study. Patients whose X-rays showed osteomyelitic 
changes were also excluded from the study. Patients who had prior surgeries 
for the same problem elsewhere were also excluded from the study. 
DESIGN OF STUDY 
 Retrospective analysis on consecutive patients admitted and treated for 
non diabetic soft tissue infections of lower limbs, followed by a prospective 
analysis on consecutive patients admitted for non diabetic soft tissue 
infections. 
STUDY POPULATION 
 Retrospective analysis included 200 patients who were admitted in 
Department of general surgery, Rajiv Gandhi Govt. General hospital during 
a period between April 2012 and April 2013. The prospective analysis 
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included 50 patients admitted with non diabetic soft tissue infection of lower 
limbs between May 2013 and October 2013. 
METHODS 
The following materials were evaluated in each patient included in the 
retrospective study 
1. Clinical data 
2. Laboratory data 
The following variables were evaluated and compared between survivors 
and non survivors and also between those who underwent a limb salvaging 
procedure or an amputation. 
1. Age in years 
2. Gender of the patient 
3. Duration of symptoms prior to admission in days 
4. Co morbid conditions 
5. Glasgow coma scale at admission 
6. Presence of sepsis as determined by the presence of two or more of 
the following - fever/ hypothermia, raise/fall of total leukocyte 
count, tachycardia and tachypnoea  
7. Requirement of ventilator support at admission 
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8. Requirement of ionotropic support at admission 
9. Urea and creatinine at admission 
10. Erythrocyte sedimentation rate at admission 
11. Total bilirubin at admission 
12. Surface area of body involved 
13. Haemoglobin in gm% at admission 
14. Depth of involvement  
Because of the large number of potentially interdependent parameters 
examined in this retrospective analysis, it was believed that a more suitable 
test for significance would reside in a multivariate analysis, using a model of 
logistic regression analysis. From the large pool of univariately significant 
variables (p < 0. 05), a smaller and more manageable group of 10 clinically 
relevant variables were selected for inclusion in the first step of the stepwise 
regression model. The selected parameters were age in years, duration of 
symptoms prior to admission in days, co morbid conditions, glasgow coma 
scale at admission, presence of sepsis as determined by the presence of two 
or more of the following - fever/ hypothermia, raise/fall of total leukocyte 
count, tachycardia and tachypnoea , requirement of ventilator support at 
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admission, requirement of ionotropic support at admission, surface area of 
body involved, haemoglobin in gm% at  admission, depth of involvement.  
The variables found on logistic regression analysis to significantly increase 
the risk of death or limb loss were used to form a scoring system. This score 
was then re applied to the retrospective study to analyze the actual outcome 
with the expected outcome. After taking the difference between the expected 
and actual outcomes into account, cut offs for the scoring system were 
established. This scoring system was then applied to a group of 50 patients 
and these patients were treated according to the score protocol. The results of 
this prospective study were then statistically analyzed.  
DATA ANALYSIS: 
To assess possible risk factors for morbidity and mortality, univariate 
analyses were completed initially to aid in determining the variables that 
should be included in a stepwise logistic regression model. Comparisons of 
proportions were made using Pearson's chi square statistic to identify 
univariate differences among defined variables with respect to mortality. 
Fisher's exact test for 2 X 2 tables was used in the small-sample case. For 
measured variables, the F statistic was used to compare means between 
survivors and non survivors. Clinically relevant variables were selected from 
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the large pool of variables with uni variate p values less than 0.05 for 
inclusion in the initial step of the logistic regression analysis. A p value of 
0.05 also was chosen as the criterion by which to judge the entry and 
removal of variables at each step of the regression procedure. Results of the 
logistic regression analysis were expressed using beta coefficient values, 
odds ratios (defined as exp[coefficient]), and 90% confidence limits for the 
odds ratios. Statistical analysis was performed using SPSS software version 
12.  
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RESULTS 
A total of 200 cases which satisfied the inclusion criteria, admitted during a 
period of April 2012 to April 2013 were analysed retrospectively. 
SAMPLE SIZE = 200 (n) 
The following are the individual parameters studied 
Age: 
Age group – 14 years to 91 years 
Mean Age of the Sample – 52.5 years 
FIGURE (1) 
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TABLE (1) Age grouping vs. outcome 
   
Outcome 
Total Amputation Limb Saved Expired 
Age Group in 
years 
Below 30 Count 10 11 0 21 
% within Age 
Group in years 47.6% 52.4% .0% 100.0% 
% within 
Outcome 
27.0% 7.1% .0% 10.5% 
31-50 Count 18 63 3 84 
% within Age 
Group in years 21.4% 75.0% 3.6% 100.0% 
% within 
Outcome 
48.6% 40.6% 37.5% 42.0% 
Above 50 Count 9 81 5 95 
% within Age 
Group in years 9.5% 85.3% 5.3% 100.0% 
% within 
Outcome 
24.3% 52.3% 62.5% 47.5% 
Total Count 37 155 8 200 
% within Age 
Group in years 18.5% 77.5% 4.0% 100.0% 
% within 
Outcome 
100.0% 100.0% 100.0% 100.0% 
Cross tabulation applied for age versus outcome of patient. P value found to 
be 0.001 (significant). Age grouping was done according to statistical 
significance, into three groups – less than 30 years, 31 – 50 years and more 
than 51 years. 
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FIGURE (2) 
 
Gender: 
No. of male patients – 121, No. of female patients – 79  
FIGURE (3) 
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Cross tabulation applied for sex versus outcome of patient. P value found to 
be 0.527 (not significant). 
Distribution of duration of disease prior to hospital admission 
Range – 1 day to 30 days 
FIGURE (4) 
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TABLE (2) Duration of disease vs. Outcome  
   
Outcome 
Total Amputation Limb Saved Expired 
Duration in 
days 
<= 5 Count 22 88 3 113 
% within 
Duration in 
days 
19.5% 77.9% 2.7% 100.0% 
% within 
Outcome 
59.5% 56.8% 37.5% 56.5% 
> 5 Count 15 67 5 87 
% within 
Duration in 
days 
17.2% 77.0% 5.7% 100.0% 
% within 
Outcome 
40.5% 43.2% 62.5% 43.5% 
Total Count 37 155 8 200 
% within 
Duration in 
days 
18.5% 77.5% 4.0% 100.0% 
% within 
Outcome 
100.0% 100.0% 100.0% 100.0% 
Cross tabulations were done between duration of disease prior to admission 
and outcome. P value was found to be significant (<0.001). Duration 
grouping was done into two statistically significant groups of less than or 
equal to 5 days and more than 5 days. 
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FIGURE (5) 
 
Distribution based on Glasgow Coma Scale (GCS)  
GCS grouping was done according to statistical significance into three 
groups, less than or equal to 8, between 9 and 12 and greater than 13. 
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FIGURE (6) 
 
TABLE (3) GCS vs. Outcome  
   
Outcome 
Total Amputation Limb Saved Expired 
GCS <= 8 Count 1 0 7 8 
% within 
GCS 
12.5% .0% 87.5% 100.0% 
% within 
Outcome 
2.7% .0% 87.5% 4.0% 
9-12 Count 1 0 0 1 
% within 
GCS 
100.0% .0% .0% 100.0% 
% within 
Outcome 
2.7% .0% .0% .5% 
> 12 Count 35 155 1 191 
% within 
GCS 
18.3% 81.2% .5% 100.0% 
% within 
Outcome 
94.6% 100.0% 12.5% 95.5% 
Total Count 37 155 8 200 
% within 
GCS 
18.5% 77.5% 4.0% 100.0% 
% within 
Outcome 
100.0% 100.0% 100.0% 100.0% 
Cross tabulation applied for GCS vs. Outcome. P value found to be 
significant in all three groups (<0.001). 
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FIGURE (7) 
 
Distribution of sepsis 
The presence of sepsis was defined by the presence of two or more of  
1) Temperature >38 or < 36 degree Celsius 
2) Tachycardia 
3) Tachypnoea 
4)  Leukocyte count >15,000/cumm or < 5,000/cumm 
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FIGURE (8) 
 
Chi squared test showed a p value of 0.004 (significant). 
Requirement of Ionotropic support 
No. of patients who required ionotropic support – 4 (2%). 
TABLE (4) Requirement of Ionotropic support vs. Outcome 
   
Outcome 
Total Amputation Limb Saved Expired 
ION Support Yes Count 1 0 3 4 
% within ION 
Support 
25.0% .0% 75.0% 100.0% 
% within 
Outcome 
2.7% .0% 37.5% 2.0% 
No Count 36 155 5 196 
% within ION 
Support 
18.4% 79.1% 2.6% 100.0% 
% within 
Outcome 
97.3% 100.0% 62.5% 98.0% 
Total Count 37 155 8 200 
% within ION 
Support 
18.5% 77.5% 4.0% 100.0% 
% within 
Outcome 
100.0% 100.0% 100.0% 100.0% 
66% 
34% 
Presence of sepsis 
Yes No
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Cross tabulations between requirement of ionotropic support vs. Outcome 
was done. P value was <0.001 (significant). 
FIGURE (9) 
 
Requirement of ventilator support 
No. of patients requiring ventilator support – 6 (3%). 
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TABLE (5) Requirement of ventilator vs. Outcome 
   
Outcome 
Total Amputation Limb Saved Expired 
Ventilator Yes Count 1 0 5 6 
% within 
Ventilator 
16.7% .0% 83.3% 100.0% 
% within 
Outcome 
2.7% .0% 62.5% 3.0% 
No Count 36 155 3 194 
% within 
Ventilator 
18.6% 79.9% 1.5% 100.0% 
% within 
Outcome 
97.3% 100.0% 37.5% 97.0% 
Total Count 37 155 8 200 
% within 
Ventilator 
18.5% 77.5% 4.0% 100.0% 
% within 
Outcome 
100.0% 100.0% 100.0% 100.0% 
Cross tabulation between ventilator requirement and outcome was done. 
P value was found to be <0.001(significant). 
FIGURE (10) 
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Distribution of surface area involved 
Body surface area (BSA) involved was assessed clinically using Wallace 
rule of nines (as for burns). 
According to statistical significance surface area grouping was done into 
three - <10% of BSA, 10 – 30% of BSA and >30% of BSA involved. 
 
FIGURE (11) 
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TABLE (6) BSA involved vs. Outcome 
   
Outcome 
Total Amputation Limb Saved Expired 
SA% <= 10 Count 16 138 1 155 
% within 
SA% 
10.3% 89.0% .6% 100.0% 
% within 
Outcome 
43.2% 89.0% 12.5% 77.5% 
11-30 Count 21 17 7 45 
% within 
SA% 
46.7% 37.8% 15.6% 100.0% 
% within 
Outcome 
56.8% 11.0% 87.5% 22.5% 
Total Count 37 155 8 200 
% within 
SA% 
18.5% 77.5% 4.0% 100.0% 
% within 
Outcome 
100.0% 100.0% 100.0% 100.0% 
Cross tabulation was done between percentage of BSA involved and 
outcome. P value was found to be <0.001 (significant). 
 
FIGURE (12) 
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Distribution of depth of involvement 
No. of cases of cellulitis (skin) – 100 (50%) 
No. of cases of necrotising fasciitis (sub cutaneous) – 95 (47.5%) 
No. of cases of pyomyonecrosis (muscle) – 5 (2.5%) 
FIGURE (13) 
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TABLE (7) Depth of involvement vs. Outcome 
   
Outcome 
Total Amputation Limb Saved Expired 
Depth Skin Count 8 92 0 100 
% within 
Depth 
8.0% 92.0% .0% 100.0% 
% within 
Outcome 
21.6% 59.4% .0% 50.0% 
Sub cut Count 27 63 5 95 
% within 
Depth 
28.4% 66.3% 5.3% 100.0% 
% within 
Outcome 
73.0% 40.6% 62.5% 47.5% 
Muscle Count 2 0 3 5 
% within 
Depth 
40.0% .0% 60.0% 100.0% 
% within 
Outcome 
5.4% .0% 37.5% 2.5% 
Total Count 37 155 8 200 
% within 
Depth 
18.5% 77.5% 4.0% 100.0% 
% within 
Outcome 
100.0% 100.0% 100.0% 100.0% 
Cross tabulation between various depths of involvement and outcome was 
done. P value was found to be <0.001 (significant). 
FIGURE (14) 
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Distribution of Co morbidities 
Presence of co morbidities other than diabetes mellitus was taken into 
consideration. Presence of more than one co morbidity statistically altered 
the outcome. 
TABLE (8) Presence of do morbidity vs. Outcome  
   
Outcome 
Total Amputation Limb Saved Expired 
Co-morbidity Yes Count 7 17 2 26 
% within Co-
morbidity 
26.9% 65.4% 7.7% 100.0% 
% within 
Outcome 
18.9% 11.0% 25.0% 13.0% 
No Count 30 138 6 174 
% within Co-
morbidity 
17.2% 79.3% 3.4% 100.0% 
% within 
Outcome 
81.1% 89.0% 75.0% 87.0% 
Total Count 37 155 8 200 
% within Co-
morbidity 
18.5% 77.5% 4.0% 100.0% 
% within 
Outcome 
100.0% 100.0% 100.0% 100.0% 
Cross tabulation done between presence of co morbidity and outcome done. 
P value found to be 0.025 (significant).  
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FIGURE (15) 
 
Distribution on Haemoglobin 
Patients grouped based on haemoglobin into two groups - <=8 and >8 
FIGURE (16) 
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TABLE (9) Haemoglobin vs. Outcome  
 
   
Outcome 
Total Amputation Limb Saved Expired 
Hb <= 8 Count 10 33 7 50 
% within 
Hb 
20.0% 66.0% 14.0% 100.0% 
% within 
Outcome 
27.0% 21.3% 87.5% 25.0% 
> 8 Count 27 122 1 150 
% within 
Hb 
18.0% 81.3% .7% 100.0% 
% within 
Outcome 
73.0% 78.7% 12.5% 75.0% 
Total Count 37 155 8 200 
% within 
Hb 
18.5% 77.5% 4.0% 100.0% 
% within 
Outcome 
100.0% 100.0% 100.0% 100.0% 
Cross tabulation showed the p value was <0.001(significant) 
FIGURE (17) 
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Distribution of Erythrocyte Sedimentation Rate (ESR) 
Distribution of ESR among the study population was not found to 
statistically alter the outcome of the patient. P value was found to be 0.255, 
statistically not significant. 
Distribution of Urea/ Creatinine 
Distribution of urea and creatinine among study population was not found to 
statistically alter the outcome of the patient. P value was found to be 0.576, 
statistically not significant. 
Distribution of Total Bilirubin  
Distribution of total bilirubin among the study population was not found to 
statistically alter the outcome of the patient. P value was found to be 0.764, 
statistically not significant. 
Treatment  
All 200 patients in the study were treated either conservatively (46) or by 
debridement (111) or by amputation (43). 
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FIGURE (18) 
 
Outcome 
The outcome of the 200 patients was analysed and defined by the mortality 
or the morbidity (amputation/ duration of hospital stay). 
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FIGURE (19) 
 
Outcome vs. Hospital stay 
The average hospital stay required per patient varied according to the 
outcome. Patients treated by conservative treatment had an average hospital 
stay of 4.76 days. Patients treated by debridement had an average hospital 
stay of 10.1 days. Patients treated by amputation had an average hospital 
stay of 12.19 days. 
Overall average number of days of hospital stay – 8.01 days. 
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FIGURE (20) 
 
Outcome vs. No. of surgeries 
The average no. of surgeries required per patients also varied according to 
the outcome. Patients who underwent debridement required an average of 
2.27 surgeries per person. Patients who underwent an amputation required an 
average of 2.67 surgeries per patient with one patient requiring 4 surgeries 
(three debridements followed by amputation). 
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TABLE (10) No. of surgeries vs. Outcome 
   
Outcome 
Total Amputation Limb Saved Expired 
No. of 
Surgeries 
Nil Count 0 46 0 46 
% within No. of 
Surgeries 
.0% 100.0% .0% 100.0% 
% within 
Outcome 
.0% 29.7% .0% 23.0% 
1 Count 19 82 4 105 
% within No. of 
Surgeries 
18.1% 78.1% 3.8% 100.0% 
% within 
Outcome 
51.4% 52.9% 50.0% 52.5% 
2 Count 15 26 4 45 
% within No. of 
Surgeries 
33.3% 57.8% 8.9% 100.0% 
% within 
Outcome 
40.5% 16.8% 50.0% 22.5% 
3 Count 2 1 0 3 
% within No. of 
Surgeries 
66.7% 33.3% .0% 100.0% 
% within 
Outcome 
5.4% .6% .0% 1.5% 
4 Count 1 0 0 1 
% within No. of 
Surgeries 
100.0% .0% .0% 100.0% 
% within 
Outcome 
2.7% .0% .0% .5% 
Total Count 37 155 8 200 
% within No. of 
Surgeries 
18.5% 77.5% 4.0% 100.0% 
% within 
Outcome 
100.0% 100.0% 100.0% 100.0% 
Cross tabulation showed that the p value was <0.001 (significant). 
A total of 200 patients’ records were thus analysed. 
MULTIVARIATE ANALYSIS 
Logistic regression analysis demonstrated that the following factors 
were independent predictors of outcome in non diabetic patients with soft 
tissue infections.  
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TABLE (11) 
SL NO. FACTOR P VALUE 
1. AGE (YEARS) <0.001 
2. DURATION OF DISEASE (DAYS) <0.001 
3. PRESENCE OF CO MORBID CONDITIONS 0.025 
4. GCS <0.001 
5. PRESENCE OF SEPSIS(as defined above) 0.004 
6. REQUIREMENT OF VENTILATOR <0.001 
7. REQUIREMENT OF IONOTROPIC SUPPORT <0.001 
8. BODY SURFACE AREA INVOLVED (%) <0.001 
9. HAEMOGLOBIN (gm %) <0.001 
10. DEPTH OF INVOLVEMENT <0.001 
 
Based on these parameters a scoring system was devised using the above ten 
mentioned parameters and scores were allotted according to the statistical 
groupings done earlier. The following was the proposed scoring system. 
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TABLE (12) 
SL 
NO. 
CRITERION 1 2 3 
1.  AGE (YEARS)  <30 30-50 >50 
2.  DURATION OF 
SYMPTOMSPRIOR 
TO 
ADMISSION(DAYS) 
<5 >5  
3.  COMORBIDITIES 1 2 >2 
4.  GCS 15 9-14 <9 
5.  PRESENCE OF 
SEPSIS 
 YES  
6.  VENTILATORY 
SUPPORT 
 YES  
7.  IONOTROPIC 
SUPPORT 
 YES  
8.  BODY SURFACE 
AREA 
<10% 10-20% >20% 
9.  HB (gm %) >8 </=8  
10. DEPTH OF 
INVOLVEMENT 
CELLULTIS EVOLVING 
NF 
NF/MYONECROSIS 
 
This scoring system was re applied to the 200 patients in the retrospective 
study and the outcomes were analysed. 
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The following were the results: 
Conservative treatment: 
No. of patients - 46 
Among the 46 patients, 44 had a score of less than 13 and only 2 patients 
had a score of 14. The average no. of days of hospital stay in this group was 
4.76 days. 
Patients who underwent debridement: 
No. of patients – 111 
Among the 111, the least score was 12 (2 patients), and the maximum score 
was 19 (17 patients). Majority of patients had a score of 17 and 18 (42 each). 
Average no. of surgeries undergone per patient was 2.27. Average no. of 
days of hospital stay in this group was 10.1 days. Among this group 2 
patients expired and both had a score of 19. 
Patients who underwent amputation: 
No. of patients – 43 
Among the 43 patients, the minimum score was 13 (3 patients) and 
maximum score was 24 (6 patients). Majority of patients had a score of 21 
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(22 patients). Average no. of surgeries per patient was 2.67 and average no. 
of days of hospital stay was 12.19 days. Among this group 6 patients 
expired, one with a score of 24 and 5 with a score of 22. 
FIGURE (21) 
 
Based on this evaluation cut offs were established for the scoring system. 
Any patient with a score less than or equal to 13 would be treated 
conservatively. Any patient with a score between 14 and 19 would be treated 
with extensive debridement and any patient with a score greater than or 
equal to 20 would undergo an amputation. 
<13
14-19
>20
3 
4 
36 
44 
2 
0 
2 
109 
0 
Score vs. Outcome 
Amputation Conservative Debridement
88 
 
This scoring system was then applied prospectively on a group of 50 patients 
who were admitted to the hospital from May 2013 to October 2013. The 
following were the results. 
Score vs. Outcome 
The scores of 50 patients was cross tabulated with the outcomes.   
TABLE (13) Score vs. Outcome 
   
Outcome 
Total Amputation Conservative Debridement 
Score <= 13 Count 0 9 1 10 
% within 
Score 
.0% 90.0% 10.0% 100.0% 
% within 
Outcome 
.0% 100.0% 3.3% 20.0% 
14-19 Count 0 0 26 26 
% within 
Score 
.0% .0% 100.0% 100.0% 
% within 
Outcome 
.0% .0% 86.7% 52.0% 
> 19 Count 11 0 3 14 
% within 
Score 
78.6% .0% 21.4% 100.0% 
% within 
Outcome 
100.0% .0% 10.0% 28.0% 
Total Count 11 9 30 50 
% within 
Score 
22.0% 18.0% 60.0% 100.0% 
% within 
Outcome 
100.0% 100.0% 100.0% 100.0% 
 
Cross tabulation showed a p value of <0.001, which was statistically 
significant. 
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FIGURE (22) 
 
Outcome vs. No. of surgeries 
The no. of surgeries required per patient was cross tabulated with the 
outcome. No patient underwent more than 2 procedures. 
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TABLE (14) Outcome vs. No. of surgeries 
   
Outcome 
Total Amputation Conservative Debridement 
No. of 
Surgeries 
Nil Count 0 9 0 9 
% within No. of 
Surgeries 
.0% 100.0% .0% 100.0% 
% within 
Outcome 
.0% 100.0% .0% 18.0% 
1 Count 11 0 10 21 
% within No. of 
Surgeries 
52.4% .0% 47.6% 100.0% 
% within 
Outcome 
100.0% .0% 33.3% 42.0% 
2 Count 0 0 20 20 
% within No. of 
Surgeries 
.0% .0% 100.0% 100.0% 
% within 
Outcome 
.0% .0% 66.7% 40.0% 
Total Count 11 9 30 50 
% within No. of 
Surgeries 
22.0% 18.0% 60.0% 100.0% 
% within 
Outcome 
100.0% 100.0% 100.0% 100.0% 
Cross tabulations showed the p value was <0.001 which was statistically 
significant. 
FIGURE (23) 
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Average no. of surgeries per person in patients undergoing debridement was 
found to be 1.67. 
Average no. of surgeries per person in patients undergoing amputation was 
found to be 1.0. 
Study of outcome vs. Hospital stay 
TABLE (15) Oneway test – Descriptive 
 N Mean 
Std. 
Deviation 
Std. 
Error 
95% Confidence Interval 
for Mean Minimum Maximum 
          
Lower 
Bound 
Upper 
Bound     
Amputation 8 9.00 1.512 .535 7.74 10.26 7 12 
Conservativ
e 
5 5.00 .707 .316 4.12 5.88 4 6 
Debridemen
t 
23 11.35 2.308 .481 10.35 12.35 7 15 
Total 36 9.94 2.976 .496 8.94 10.95 4 15 
 
The test showed that the average no. of days of hospital stay in a patient 
undergoing conservative treatment was 5 days, undergoing debridement was 
11.35 days, and undergoing amputation was 9 days. 
TABLE (16) ANOVA - Hospital stay 
 
 
Sum of 
Squares df Mean Square F Sig. 
Between Groups 174.671 2 87.336 21.314 <0.001 
Within Groups 135.217 33 4.097     
Total 309.889 35       
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The ANOVA test showed that procedure undergone by the patient 
determined the hospital stay of the patient. 
TABLE (17) Post Hoc Tests -  Multiple Comparisons 
 
Dependent Variable: Hospital Stay  
(I) Outcome (J) Outcome 
Mean 
Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Amputation Conservative 4.00(*) 1.154 .004 1.17 6.83 
Debridement -2.35(*) .831 .021 -4.39 -.31 
Conservative Amputation -4.00(*) 1.154 .004 -6.83 -1.17 
  Debridement -6.35(*) .999 .000 -8.80 -3.90 
Debridement Amputation 2.35(*) .831 .021 .31 4.39 
  Conservative 6.35(*) .999 .000 3.90 8.80 
 
Multiple comparisons through post hoc test showed that inter group 
comparisons were statistically significant. (all p values <0.05). 
Mortality vs. Procedure done 
TABLE (19) Procedure done vs. Mortality 
   
Outcome 
Total Amputation Conservative Debridement 
Mortality Yes Count 3 0 7 10 
% within 
Mortality 
30.0% .0% 70.0% 100.0% 
% within 
Outcome 
27.3% .0% 23.3% 20.0% 
No Count 8 9 23 40 
% within 
Mortality 
20.0% 22.5% 57.5% 100.0% 
% within 
Outcome 
72.7% 100.0% 76.7% 80.0% 
Total Count 11 9 30 50 
% within 
Mortality 
22.0% 18.0% 60.0% 100.0% 
% within 
Outcome 
100.0% 100.0% 100.0% 100.0% 
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Cross tabulation was done and p value was found to be 0.244 (not 
significant). Therefore the procedure per se is not directly responsible for the 
mortality of the patient, but preoperative condition of the patient is the 
determining factor. The mortality was found to be 20%. 
Comparison of hospital stay in the retrospective and prospective study: 
FIGURE (24) 
 
Cross tabulation done between no. of days of hospital stay in each group in 
the retrospective study to the prospective study. P value in all cases was not 
statistically significant. 
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TABLE (20) 
 RETROSPECTIVE 
STUDY 
PROSPECTIVE 
STUDY 
P VALUE 
CONSERVATIVE  4.76 5 0.472 (not significant) 
DEBRIDEMENT 10.1 9 0.142(not significant) 
AMPUTATION 12.19 11.35 0.576(not significant) 
 
Comparison of no. of surgeries undergone per person in retrospective 
and prospective study: 
FIGURE (25) 
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Cross tabulation done between the no. of surgeries in retrospective and 
prospective studies and the outcome. 
TABLE (21) 
Treatment   
  
Study 
Total   
Retrospective 
study 
Prospective 
study 
Amputation No. of 
Surgeries 
1 Count 
23 11 34 
  % within No. of 
Surgeries 
67.6% 32.4% 100.0% 
% within Study 53.5% 100.0% 63.0% 
2 Count 17 0 17 
% within No. of 
Surgeries 
100.0% .0% 100.0% 
% within Study 39.5% .0% 31.5% 
3 Count 2 0 2 
% within No. of 
Surgeries 
100.0% .0% 100.0% 
% within Study 4.7% .0% 3.7% 
4 Count 1 0 1 
% within No. of 
Surgeries 
100.0% .0% 100.0% 
% within Study 2.3% .0% 1.9% 
Total Count 43 11 54 
  % within No. of 
Surgeries 
79.6% 20.4% 100.0% 
% within Study 100.0% 100.0% 100.0% 
Debridement No. of 
Surgeries 
1 Count 
82 10 92 
    % within No. of 
Surgeries 
89.1% 10.9% 100.0% 
% within Study 73.9% 33.3% 65.2% 
2 Count 28 20 48 
% within No. of 
Surgeries 
58.3% 41.7% 100.0% 
% within Study 25.2% 66.7% 34.0% 
3 Count 1 0 1 
% within No. of 
Surgeries 
100.0% .0% 100.0% 
% within Study .9% .0% .7% 
Total Count 111 30 141 
  % within No. of 
Surgeries 
78.7% 21.3% 100.0% 
% within Study 100.0% 100.0% 100.0% 
 
P value for the first group (amputation) was 0.043 and for the second group 
(debridement) was <0.001. The comparison was statistically significant 
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showing that there is a statistically significant decrease in the no. of 
surgeries undergone by each patient in both the groups. 
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DISCUSSION 
Necrotizing soft tissue infections of the skin have been reported to 
have a high morbidity and mortality. In 1924, Meleney
[115]
 noted a mortality 
rate of 20% out of 20 patients. The mortality rate of 20% in the present 
series is slightly lower than the cumulative mortality of 34% as reported in 
the Mchenry et al. study
[116]
. Wong et al.
[117]
, in their series of 89 patients, 
70% involving lower limbs, have a mortality rate of 21.3%. Singh et al.,
[118]
 
in their series of 55 patients (31 involving lower limbs) reported a mortality 
of 27.2%. Tang et al.,
[119]
 with 24 patients with necrotizing fasciitis of the 
limbs, in which 12 involved the lower limbs, reported a mortality of 33.3%. 
As we know necrotizing fasciitis of the lower limbs are more amenable for 
local control as amputation can be performed to control the local effect of 
the disease, whereas necrotizing fasciitis that involves trunk and 
genitourinary systems is more difficult to control since wound debridement 
hindered and not as thorough because it involves vital organs. Thus, lower 
limb involvement gives a more favourable outcome and a lower mortality 
rate. 
In the current study, we studied various parameters which are 
considered risk factors for morbidity and mortality by various authors. 
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Several authors
[56][20][19]
 reported that  patients above the age of 60 were 
associated with higher mortality. Our study showed that an age above 51 
years increased the morbidity and mortality of the patients. Other 
confounding factors must be taken into consideration as elderly patients are 
predisposed to illnesses such as diabetes mellitus and renal failure and their 
immunological status is generally poorer, all of which may contribute to the 
higher mortality rate. According to our study gender of the individual did not 
contribute to morbidity or mortality, contrary to results reported by Elliot et 
al. 
[120]
. Initial presentation of necrotizing fasciitis is easily confused with 
other milder soft tissue infections such as cellulitis which require only a 
conservative treatment approach. Unfortunately, this can delay definitive 
treatment of debridement or amputation. According to our study a duration 
of greater than five days duration between initial symptoms and surgical 
procedure is associated with a higher rate of morbidity and mortality similar 
to the results of Eckmann et al. 
[121]
, who that noted those with a duration of 
initial symptoms to surgical treatment of more than 5 days were associated 
with a higher mortality rate. Although little can be done to influence the time 
between a patient development of symptoms and receipt of medical attention 
except to increase public awareness through education, measures can be 
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taken to hasten the diagnosis and early operative debridement. Wong et al. 
[117]
 developed a screening system for necrotizing fasciitis with a high 
predictive value that is helpful in making an early diagnosis, leading to 
situations where definitive treatment can be carried out as early as possible. 
The presence of sepsis at the time of admission was defined by the presence 
of two or more of the following, increase or decrease of body temperature, 
increase or decrease of total leukocyte count, tachycardia and tachypnoea. 
There was significant effect of temperature on admission on morbidity and 
mortality in the present study, similar to results published by Bosshardt et al. 
[122]
 in which high admission temperature was identified as a risk factor of 
mortality. We did not find that admission blood pressure affected mortality, 
contrary to reports by Bosshart et al. and Fustes-Morales et al. who  
identified low blood pressure as a determinant for mortality 
[122][123]
. The 
presence of co morbid condition apart from Diabetes mellitus was found to 
significantly contribute to the morbidity and mortality as was seen in the 
study by Brand et al. and Elliot et al. 
[121][116]
. The consciousness of the 
patient as assessed by the Glasgow coma scale at the time of admission 
showed that a GCS of less than 13 affected the morbidity and mortality 
adversely, more so if the GCS was less than 8. This was similar to the results 
100 
 
of Darke et al.
[124]
 who showed that a GCS of less than 7 significantly 
affected the mortality. The surgical literature has been divided regarding the 
impact of extent of infection on survival; in this study, patients with less 
extensive infection, expressed in terms of body surface area involved (much 
as for burns), had a definite survival advantage, whereas such an association 
was not borne out in the study of 57 patients with Fournier's gangrene by 
Clayton et al.
[125]
. Similarly depth of infection adversely affected the 
mortality in our study. But there are no similar results in any of the 
published studies. In many other published reports, no instances of 
myonecrosis were even reported; in others, it was rare.
[122][124]
 . Among the 
lab parameters that were studied, haemoglobin was found to adversely affect 
the morbidity and mortality if it was less than 8. This was similar to the 
results published by Patino et al.
[126]
. According to our study blood urea, 
serum creatinine, erythrocyte sedimentation rate or total bilirubin values at 
the time of admission were not significant contributory factors to morbidity 
and mortality. 
The scoring system established by our study did not affect mortality. 
The usage of the scoring system in the prospective study showed a 
significant reduction in the number of procedures required by a patient. Even 
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though the usage of the scoring system showed a decrease in the number of 
days of hospital stay, the decrease was not statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
102 
 
CONCLUSION 
Skin and soft tissue infections of the limbs have a high mortality and 
morbidity especially if necrosis is present. The morbidity is in the form of 
prolonged hospital stay and limb loss. Our study does not show any change 
in the percentage of people undergoing an amputation, but it does show a 
decrease in hospital stay for the same patients, even though it is not 
statistically significant. Since our sample size is small, this aspect of the 
study might require more evaluation with a larger sample size to get 
statistically significant results. Further the retrospective study showed that 
patients underwent multiple procedures and sometimes required an 
amputation after said procedures. Our prospective study showed a 
statistically significant decrease in the number of procedures undergone per 
patient. Therefore the scoring system may be used to decrease the number of 
procedures undergone by a patient and thereby decrease psychological stress 
to the patient and help in saving unnecessary hospital expenditure. Although 
our study has showed a statistical significance in decreasing the number of 
procedures required by a patient at admission, it requires further detailed 
studies to produce repeated significant results. This is essential for the 
scoring system to be applied as an established protocol. Our current study is 
also limited by the small sample size of the prospective pool. Diabetes 
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mellitus has been identified as co-morbidity in most large studies conducted. 
Since our study excludes this co morbidity, further evaluation will be needed 
to maybe modify the scoring system including Diabetes as one of the 
variables. 
Our study also does not take into account the delay between admission 
and surgery which according to certain studies
[122]
 alters the morbidity and 
mortality. We did not have data in our retrospective study which described 
the adequateness of debridement and therefore we have not described the 
criteria which would signify an adequate debridement in our prospective 
study. Establishing fixed criteria for the same might help decrease the 
number of procedures further. This requires further study with large sample 
sizes. 
The biggest short coming would perhaps be the fact that we did not 
include microbiology of the infection in our study as the same was not 
available in all the cases studied retrospectively, and according to Wong et 
al.
[122]
 this variable significantly alters the outcome. In conclusion, if 
validated, this prediction system may improve patient outcomes by reducing 
unnecessary procedures and unnecessary wastage of hospital revenue and 
man power. Except for those patients with overwhelming risk factors for 
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dying at the time of admission (e.g., more than 4 organ systems in failure 
combined with profound metabolic acidosis), aggressive resuscitation, 
surgical debridement, and intensive care results in survival for three fourths 
of the patients presenting with necrotizing soft tissue infections. 
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PROFORMA 
 
NAME:           AGE:   IP NO. 
D.O.A:      D.O.D: 
HISTORY: 
COMPLAINTS: 
DURATION OF SYMPTOMS PRIOR TO ADMISSION: 
H/S/O SEPSIS: 
COMORBID CONDITIONS: 
TREATMENT HISTORY: 
EXAMINATION: 
GCS:     PR:    BP: 
TEMP.:     ICTERUS: 
SYSTEMS: CVS:      P/A: 
  RS:      CNS: 
LOCAL EXAMINATION: 
SURFACE AREA INVOLVED: 
DEPTH OF INVOLVEMENT: 
INVESTIGATIONS: 
CBC:        RFT: 
HB:        BLOOD SUGAR: 
HCT:        BLOOD UREA: 
TLC:        SERUM CREATININE: 
DC:        SODIUM: 
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ESR:        POTASSIUM: 
LFT: 
TOTAL BILIRUBIN:     X RAY FINDING: 
DIRECT BILIRUBIN: 
AST: 
ALT:        PUS C/S: 
ALP: 
TOTAL PROTEINS: 
SERUM ALBUMIN: 
WHETHER PATIENT IS IN SEPSIS:  YES/  NO 
DIAGNOSIS: CELLULITIS/ABCESS/NECROTISING FASCIITIS 
TREATMENT: ANTIBIOTICS/LIMBSALVAGE/AMPUTATION 
   IONOTROPIC SUPPORT: YES/NO 
   VENTILATORY SUPPORT: YES/NO 
NO. OF DAYS OF HOSPITAL STAY: 
FINAL OUTCOME: 
  CONVALESCING 
  REQUIRED AMPUTATION 
  EXPIRED 
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SCORE: 
SL NO. CRITERION 1 2 3 
1.  AGE (YEARS)  <30 30-50 >50 
2.  DURATION OF 
SYMPTOMSPRIOR TO 
ADMISSION(DAYS) 
<5 >5  
3.  COMORBIDITIES 1 2 >2 
4.  GCS 15 9-14 <9 
5.  PRESENCE OF SEPSIS  YES  
6.  VENTILATORY SUPPORT  YES  
7.  IONOTROPIC SUPPORT  YES  
8.  BODY SURFACE AREA <10% 10-20% >20% 
9.  HB (gm%) >8 </=8  
10. DEPTH OF 
INVOLVEMENT 
CELLULTIS EVOLVING 
NF 
NF 
 
TOTAL SCORE: 
 
 
 
 
 
 
 
108 
 
BIBLIOGRAPHY 
1. Morantes MC & Lipsky B. Flesh-eating bacteria: return of an old 
nemesis. Int J Derm 1995; 34(7):461-63. 
2. Quirk WF Jr, Sternbach G. Joseph Jones: infection with flesh eating 
bacteria. J Emerg Med. Nov-Dec 1996;14(6):747-53.  
3. Fournier A. Gangrene foudroyante de la verge. Semaine Med. 
1883;3:345. 
4. Meleney FL. Hemolytic streptococcus gangrene. Arch Surg. 
1924;9:317-364. 
5. Meleney FL. Haemolytic streptococcal gangrene. Importance of 
early diagnosis and early operation. J Am Med Assoc 1929;92:2009-
12. 
6. Wilson B. Necrotizing fasciitis. Am Surg. Apr 1952;18(4):416-31.  
7. Cartwright K, Logan M, McNulty C, Harrison S, George R, 
Efstratiou A, McEvoy M & Begg N. A cluster of cases of 
streptococcal necrotizing fasciitis in Gloucestershire. Epi & Inf 1995; 
115:387-97. 
109 
 
8. Kotrappa K, Bansal R & Amin N. Necrotizing fasciitis. Am Fam 
Phys 1996; 53(5):1691-96. 
9. Nowak R. Flesh-eating bacteria not new, but still worrisome. Science  
264(5166):1665. 
10. Sarani, B., Strong, M., Pascual, J., & Schwab, C. W. (2009). 
Necrotizing fasciitis: Current concepts and review of the literature. 
Journal of the American College of Surgeons, 208(2), 279‐288. 
doi:10.1016/j.jamcollsurg.2008.10.032 
11. Napolitano, L. M. (2009). Severe soft tissue infections. Infectious 
Disease Clinics of North America, 23(3), 571‐591. 
doi:10.1016/j.idc.2009.04.006 
12. Bahebeck J, Sobgui E, Loic F, Nonga BN, Mbanya JC, Sosso M. 
Limb-threatening and life-threatening diabetic extremities: clinical 
patterns and outcomes in 56 patients. J Foot Ankle Surg. Jan-Feb 
2010;49(1):43-6. 
13. May, A. K. (2009). Skin and soft tissue infections. The Surgical 
Clinics of North America, 89(2), 403‐20, viii. 
doi:10.1016/j.suc.2008.09.006 
110 
 
14. Conly J., "Chapter 55. Soft Tissue Infections" (Chapter). Hall JB, 
Schmidt GA, Wood LDH: Principles of Critical Care, 3e 
15. Quirk WF Jr, Sternbach G. Joseph Jones: infection with flesh 
eating bacteria. J Emerg Med. Nov-Dec 1996;14(6):747-53. 
16. Bahebeck J, Sobgui E, Loic F, Nonga BN, Mbanya JC, Sosso M. 
Limb-threatening and life-threatening diabetic extremities: clinical 
patterns and outcomes in 56 patients. J Foot Ankle Surg. Jan-Feb 
2010;49(1):43-6.  
17. Stone DR, Gorbach SL. Necrotizing fasciitis. The changing 
spectrum. Dermatol Clin. Apr 1997;15(2):213-20.  
18. Rouse TM, Malangoni MA, Schulte WJ. Necrotizing fasciitis: a 
preventable disaster. Surgery. Oct 1982;92(4):765-70. . 
19. Andreasen TJ, Green SD, Childers BJ. Massive infectious soft-
tissue injury: diagnosis and management of necrotizing fasciitis and 
purpura fulminans. Plast Reconstr Surg. Apr 1 2001;107(4):1025-
35. . 
111 
 
20. McHenry CR, Piotrowski JJ, Petrinic D, Malangoni MA. 
Determinants of mortality for necrotizing soft-tissue infections. Ann 
Surg. May 1995;221(5):558-63; discussion 563-5.  
21. Giuliano A, et al. Bacteriology of necrotizing fasciitis. Am J Surg 
1977;134:52-7. 
22. Miller et al. Necrotizing fasciitis caused by community 
associated MRSA in LA. N Eng J Med 2005;352:1445-53. 
23. Tang HJ, et al. In vitro and in vivo activities of newer 
fluoroquinolones against Vibro vulnificus. Antimicrob Agents 
Chemother 2002;46;3580-4. 
24. Bross MH, et al. Vibro vunificus infection: diagnosis and 
treatment. Am Fam Phy 2007;76:539-44. 
25. McLellan E, et al. Fatal NF caused by H. influenzae serotype f. J 
Med Microbio 2008;57;249-51. 
26. Olsen RJ, Musser JM. Molecular Pathogenesis of NF. Annu Rev 
Pathol Mech Dis 2010;5:1-31. 
27. Sarani B, et al. NF: Current concepts and review of Literature. J 
Am Coll Surg 2009;208(2):279-88. 
112 
 
28. Morgan WR, Caldwell MD, Brady JM, Stemper ME, Reed KD, 
Shukla SK. Necrotizing fasciitis due to a methicillin-sensitive 
Staphylococcus aureus isolate harboring an enterotoxin gene 
cluster. J Clin Microbiol. Feb 2007;45(2):668-71. 
29. Cheng NC, Chang SC, Kuo YS, Wang JL, Tang YB. Necrotizing 
fasciitis caused by methicillin-resistant Staphylococcus aureus 
resulting in death. A report of three cases. J Bone Joint Surg Am. 
May 2006;88(5):1107-10.  
30. Olsen RJ, Sitkiewicz I, Ayeras AA, et al. Decreased necrotizing 
fasciitis capacity caused by a single nucleotide mutation that alters a 
multiple gene virulence axis. Proc Natl Acad Sci U S A. Jan 12 
2010;107(2):888-93.  
31. Lehman D, Tseng CW, Eells S, et al. Staphylococcus aureus 
Panton-Valentine leukocidin targets muscle tissues in a child with 
myositis and necrotizing fasciitis. Clin Infect Dis. Jan 1 
2010;50(1):69-72.  
113 
 
32. Kim HJ, Kim DH, Ko DH. Coagulase-positive staphylococcal 
necrotizing fasciitis subsequent to shoulder sprain in a healthy 
woman. Clin Orthop Surg. Dec 2010;2(4):256-9.  
33. Tang WM, Ho PL, Yau WP, Wong JW, Yip DK. Report of 2 
fatal cases of adult necrotizing fasciitis and toxic shock syndrome 
caused by Streptococcus agalactiae. Clin Infect Dis. Oct 
2000;31(4):E15-7. 
34.  Sendi P, Johansson L, Dahesh S, et al. Bacterial phenotype 
variants in group B streptococcal toxic shock syndrome. Emerg 
Infect Dis. Feb 2009;15(2):223-32.  
35. Parcell BJ, Wilmshurst AD, France AJ, Motta L, Brooks T, Olver 
WJ. Injection anthrax causing compartment syndrome and 
necrotising fasciitis. J Clin Pathol. Jan 2011;64(1):95-6.  
36. Tang WM, Fung KK, Cheng VC, Lucke L. Rapidly progressive 
necrotising fasciitis following a stonefish sting: a report of two 
cases. J Orthop Surg (Hong Kong). Apr 2006;14(1):67-70.  
114 
 
37. Snider JM, McNabney WK & Pemberton LB. Necrotizing 
fasciitis secondary to discoid lupus erythematosus. Am Surg 1993; 
59:164-67. 
38. Bisno A & Stevens D. Streptococcal infections of skin and soft 
tissues. New Eng J Med 1996; 334(4):240-44. 
39. Simsek Celik A, Erdem H, Guzey D, et al. Fournier's gangrene: 
series of twenty patients. Eur Surg Res. 2011;46(2):82-6.  
40. Hsiao CT, Weng HH, Yuan YD, Chen CT, Chen IC. Predictors 
of mortality in patients with necrotizing fasciitis. Am J Emerg Med. 
Feb 2008;26(2):170-5.  
41. Lee CY, Kuo LT, Peng KT, Hsu WH, Huang TW, Chou YC. 
Prognostic factors and monomicrobial necrotizing fasciitis: gram-
positive versus gram-negative pathogens. BMC Infect Dis. Jan 5 
2011;11:5. 
42. Cheng NC, Su YM, Kuo YS, Tai HC, Tang YB. Factors affecting 
the mortality of necrotizing fasciitis involving the upper 
extremities. Surg Today. 2008;38(12):1108-13.  
115 
 
43. Mao JC, Carron MA, Fountain KR, et al. Craniocervical 
necrotizing fasciitis with and without thoracic extension: 
management strategies and outcome. Am J Otolaryngol. Jan-Feb 
2009;30(1):17-23.  
44. Light TD, Choi KC, Thomsen TA, et al. Long-term outcomes of 
patients with necrotizing fasciitis. J Burn Care Res. Jan-Feb 
2010;31(1):93-9.  
45. Olafsson EJ, Zeni T, Wilkes DS. A 46-year-old man with 
excruciating shoulder pain. Chest. Mar 2005;127(3):1039-44.  
46.  Iwata Y, Sato S, Murase Y, et al. Five cases of necrotizing 
fasciitis: lack of skin inflammatory signs as a clinical clue for the 
fulminant type. J Dermatol. Nov 2008;35(11):719-25.  
47. Ruth-Sahd LA & Pirrung M. The infection that eats patients 
alive. RN 1997; March:28-35. 
48. Francis KR, Lamaute HR, Davis JM & Pizzi WF. Implications of 
risk factors in necrotizing fasciitis. Am Surg 1993; 59:304-08. 
49. Bellapianta JM, et al. Necrotizing fasciitis. J Am Acad Orthop 
Surg 2009;17(3):174-82. 
116 
 
50. Simonart T, Simonart JM, Derdelinckx I, et al. Value of standard 
laboratory tests for the early recognition of group A beta-hemolytic 
streptococcal necrotizing fasciitis. Clin Infect Dis. Jan 
2001;32(1):E9-12.  
51. Drake DB, Woods JA, Bill TJ, et al. Magnetic resonance imaging 
in the early diagnosis of group A beta streptococcal necrotizing 
fasciitis: a case report. J Emerg Med. May-Jun 1998;16(3):403-7.  
52. Fugitt JB, Puckett ML, Quigley MM, Kerr SM. Necrotizing 
fasciitis. Radiographics. Sep-Oct 2004;24(5):1472-6.  
53. Chao HC, Kong MS, Lin TY. Diagnosis of necrotizing fasciitis in 
children. J Ultrasound Med. Apr 1999;18(4):277-81.  
54. Sharif HS, Clark DC, Aabed MY, Aideyan OA, Haddad MC, 
Mattsson TA. MR imaging of thoracic and abdominal wall 
infections: comparison with other imaging procedures. AJR Am J 
Roentgenol. May 1990;154(5):989-95.  
55. Wang YS, et al. Staging of NF based on the evolving cutaneous 
features. Int J Dermatol 2007;46(10):1036-41 
117 
 
56. Wong CH, Chang HC, Pasupathy S, Khin LW, Tan JL, Low CO. 
Necrotizing fasciitis: clinical presentation, microbiology, and 
determinants of mortality. J Bone Joint Surgery Am 2003;85-
A(8):1454-60 
57. Namias N, Martin L, Matos L, Sleeman D, Snowdon B. 
Symposium: necrotizing fasciitis. Contemp Surg. 1996;49:167-78. 
58. Lille ST, Sato TT, Engrav LH, Foy H, Jurkovich GJ. Necrotizing 
soft tissue infections: Obstacles in diagnosis. J Am Coll Surg. 
1995;182(1):7-11. 
59. Ramirez-Schrempp D, Dorfman DH, Baker WE, Liteplo AS. 
Ultrasound soft-tissue applications in the pediatric emergency 
department: to drain or not to drain?. Pediatr Emerg Care. Jan 
2009;25(1):44-8. 
60. Wronski M, Slodkowski M, Cebulski W, Karkocha D, 
Krasnodebski IW. Necrotizing fasciitis: early sonographic 
diagnosis. J Clin Ultrasound. May 2011;39(4):236-9.  
118 
 
61. Parenti GC, Marri C, Calandra G, Morisi C, Zabberoni W. 
[Necrotizing fasciitis of soft tissues: role of diagnostic imaging and 
review of the literature]. Radiol Med. May 2000;99(5):334-9. 
62. Beltran J, McGhee RB, Shaffer PB, et al. Experimental infections 
of the musculoskeletal system: evaluation with MR imaging and Tc-
99m MDP and Ga-67 scintigraphy. Radiology. Apr 
1988;167(1):167-72. 
63.  Tang JS, Gold RH, Bassett LW, Seeger LL. Musculoskeletal 
infection of the extremities: evaluation with MR imaging. Radiology. 
Jan 1988;166(1 Pt 1):205-9.  
64. Rahmouni A, Chosidow O, Mathieu D, et al. MR imaging in 
acute infectious cellulitis. Radiology. Aug 1994;192(2):493-6.  
65. Craig JG. Infection: ultrasound-guided procedures. Radiol Clin 
North Am. Jul 1999;37(4):669-78.  
66.  Arslan A, Pierre-Jerome C, Borthne A. Necrotizing fasciitis: 
unreliable MRI findings in the preoperative diagnosis. Eur J Radiol. 
Dec 2000;36(3):139-43.  
119 
 
67. Childers BJ, Potyondy LD, Nachreiner R, et al. Necrotizing 
fasciitis: a fourteen-year retrospective study of 163 consecutive 
patients. Am Surg. Feb 2002;68(2):109-16.  
68. Stamenkovic I, Lew PD. Early recognition of potentially fatal 
necrotizing fasciitis. The use of frozen-section biopsy. N Engl J Med. 
Jun 28 1984;310(26):1689-93. . 
69. Bakleh M, Wold LE, Mandrekar JN, Harmsen WS, Dimashkieh 
HH, Baddour LM. Correlation of histopathologic findings with 
clinical outcome in necrotizing fasciitis. Clin Infect Dis. Feb 1 
2005;40(3):410-4.  
70. Uman SJ, Kunin CM. Needle aspiration in the diagnosis of soft 
tissue infections. Arch Intern Med. Jul 1975;135(7):959-61.  
71. Francis J, Warren RE. Streptococcus pyogenes bacteraemia in 
Cambridge--a review of 67 episodes. Q J Med. Aug 
1988;68(256):603-13.  
72. Chelsom J, Halstensen A, Haga T, Hoiby EA. Necrotising 
fasciitis due to group A streptococci in western Norway: incidence 
and clinical features. Lancet. Oct 22 1994;344(8930):1111-5.   
120 
 
73. Edlich RF, Wind TC, Heather CL, Thacker JG. Reliability and 
performance of innovative surgical double-glove hole puncture 
indication systems. J Long Term Eff Med Implants. 2003;13(2):69-
83.   
74. Wang KC, Shih CH. Necrotizing fasciitis of the extremities. J 
Trauma. Feb 1992;32(2):179-82.   
75. Kaufman JL. Clinical problem-solving: necrotizing fasciitis. N 
Engl J Med. Jul 28 1994;331(4):279; author reply 280.   
76. Adams EM, Gudmundsson S, Yocum DE, Haselby RC, Craig 
WA, Sundstrom WR. Streptococcal myositis. Arch Intern Med. Jun 
1985;145(6):1020-3.   
77. Gear AJ, Hellewell TB, Wright HR, et al. A new silver 
sulfadiazine water soluble gel. Burns. Aug 1997;23(5):387-91.   
78. Frame JD, Still J, Lakhel-LeCoadou A, et al. Use of dermal 
regeneration template in contracture release procedures: a 
multicenter evaluation. Plast Reconstr Surg. Apr 15 
2004;113(5):1330-8.   
121 
 
79. Wainwright DJ. Use of an acellular allograft dermal matrix 
(AlloDerm) in the management of full-thickness burns. Burns. Jun 
1995;21(4):243-8.   
80. Stevens DL, Yan S, Bryant AE. Penicillin-binding protein 
expression at different growth stages determines penicillin efficacy 
in vitro and in vivo: an explanation for the inoculum effect. J Infect 
Dis. Jun 1993;167(6):1401-5.   
81. Yan S, Bohach GA, Stevens DL. Persistent acylation of high-
molecular-weight penicillin-binding proteins by penicillin induces 
the postantibiotic effect in Streptococcus pyogenes. J Infect Dis. Sep 
1994;170(3):609-14.   
82. Gemmell CG, Peterson PK, Schmeling D, et al. Potentiation of 
opsonization and phagocytosis of Streptococcus pyogenes following 
growth in the presence of clindamycin. J Clin Invest. May 
1981;67(5):1249-56.   
83. Stevens DL, Bryant AE, Yan S. Invasive group A streptococcal 
infection: New concepts in antibiotic treatment. Int J Antimicrob 
Agent. 1994;4:297-301. 
122 
 
84. Stevens DL, Bryant AE, Hackett SP. Antibiotic effects on 
bacterial viability, toxin production, and host response. Clin Infect 
Dis. Jun 1995;20 Suppl 2:S154-7.   
85. Edlich RF, Winters KL, Woodard CR, Britt LD, Long WB 3rd. 
Massive soft tissue infections: necrotizing fasciitis and purpura 
fulminans. J Long Term Eff Med Implants. 2005;15(1):57-65.   
86. Lota AS, Altaf F, Shetty R, Courtney S, McKenna P, Iyer S. A 
case of necrotising fasciitis caused by Pseudomonas aeruginosa. J 
Bone Joint Surg Br. Feb 2010;92(2):284-5.   
87. Barry W, Hudgins L, Donta ST, Pesanti EL. Intravenous 
immunoglobulin therapy for toxic shock syndrome.JAMA. Jun 24 
1992;267(24):3315-6.   
88. Yong JM. Necrotising fasciitis. Lancet. Jun 4 
1994;343(8910):1427.   
89. Darenberg J, Ihendyane N, Sjolin J, et al. Intravenous 
immunoglobulin G therapy in streptococcal toxic shock syndrome: a 
European randomized, double-blind, placebo-controlled trial. Clin 
Infect Dis. Aug 1 2003;37(3):333-40.   
123 
 
90. Norrby-Teglund A, Muller MP, Mcgeer A, et al. Successful 
management of severe group A streptococcal soft tissue infections 
using an aggressive medical regimen including intravenous 
polyspecific immunoglobulin together with a conservative surgical 
approach. Scand J Infect Dis. 2005;37(3):166-72.  
91. Sarani B, Strong M, Pascual J, Schwab CW. Necrotizing fasciitis: 
current concepts and review of the literature. J Am Coll Surg. Feb 
2009;208(2):279-88.   
92. Korhonen K. Hyperbaric oxygen therapy in acute necrotizing 
infections with a special reference to the effects on tissue gas 
tensions. Ann Chir Gynaecol Suppl. 2000;7-36.   
93. Korhonen K, Kuttila K, Niinikoski J. Tissue gas tensions in 
patients with necrotising fasciitis and healthy controls during 
treatment with hyperbaric oxygen: a clinical study. Eur J Surg. Jul 
2000;166(7):530-4.  
94. Krenk L, Nielsen HU, Christensen ME. Necrotizing fasciitis in 
the head and neck region: an analysis of standard treatment 
effectiveness. Eur Arch Otorhinolaryngol. Aug 2007;264(8):917-22.   
124 
 
95. Sugihara A, Watanabe H, Oohashi M, et al. The effect of 
hyperbaric oxygen therapy on the bout of treatment for soft tissue 
infections. J Infect. May 2004;48(4):330-3.   
96. Green RJ, Dafoe DC, Raffin TA. Necrotizing fasciitis. Chest. Jul 
1996;110(1):219-29.   
97. Riseman JA, Zamboni WA, Curtis A, Graham DR, Konrad HR, 
Ross DS. Hyperbaric oxygen therapy for necrotizing fasciitis reduces 
mortality and the need for debridements. Surgery. Nov 
1990;108(5):847-50.  
98. Brown DR, Davis NL, Lepawsky M, Cunningham J, Kortbeek J. 
A multicenter review of the treatment of major truncal necrotizing 
infections with and without hyperbaric oxygen therapy. Am J Surg. 
May 1994;167(5):485-9.  
99. Monestersky JH, Myers RA. Hyperbaric oxygen treatment of 
necrotizing fasciitis. Am J Surg. Jan 1995;169(1):187-8.   
100. Meyer-Heine A, Huguenin P. Traitement de l'erysipele par la 
chlorhydrate de sulfamidochrysoidine [Treatment of erysipelas with 
sulfamido-chrysoidin chlorhydrate]. Presse Med 1936;44:454-457. 
125 
 
101. Snodgrass WR, Anderson T. Prontosil in the treatment of 
erysipelas: a controlled series of 312 cases. Br Med 
J 1937;2((3933)):101-104. 
102. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-
resistant S. aureusinfections among patients in the emergency 
department. N Engl J Med2006;355:666-674. 
103. Moellering RC Jr. The growing menace of community-acquired 
methicillin-resistantStaphylococcus aureus. Ann Intern 
Med 2006;144:368-370. 
104. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-
resistant Staphylococcus aureus disease in three communities. N 
Engl JMed 2005;352:1436-1444. 
105. Chambers HF. Community-associated MRSA—resistance and 
virulence converge. N Engl J Med 2005;352:1485-1487. 
106.  Daum RS. Clinical practice: skin and soft-tissue infections 
caused by methicillin-resistant Staphylococcus aureus. N Engl J 
Med 2007;357:380-390. 
126 
 
107.  Hersh AL, Chambers HF, Maselli JH, Gonzales R. National 
trends in ambulatory visits and antibiotic prescribing for skin and 
soft-tissue infections. Arch Intern Med2008;168:1585-1591. 
108.  Chambers HF, Moellering RC Jr., Kamitsuka P. Clinical 
decisions: management of skin and soft-tissue infection. N Engl J 
Med 2008;359:1063-1067. 
109.  Spellberg B, Boucher HW, Bradley J, Das A, Talbot GH. To 
treat or not to treat: adjunctive antibiotics for uncomplicated 
abscesses. Ann Emerg Med. (in press). 
110.  Spellberg B, Talbot GH, Boucher HW, et al. Antimicrobial 
agents for complicated skin and skin-structure infections: 
justification of noninferiority margins in the absence of 
placebocontrolled trials. Clin Infect Dis 2009;49:383-391. 
111.  US Department of Health and Human Services, Food and Drug 
Administration, Center for Drug Evaluation and Research 
(CDER). Draft guidance for industry: acute bacterial skin and skin 
structure infections—developing drugs for treatment. August 2010. 
112.  Jenkins TC, Sabel AL, Sarcone EE, Price CS, Mehler PS, Burma
n WJ. Skin and soft-tissue infections requiring hospitalization at an 
127 
 
academic medical center: opportunities for antimicrobial 
stewardship. Clin Infect Dis 2010;51((8)):895-903.(in this issue). 
113.  Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines 
for the diagnosis andmanagement of skin and soft-tissue 
infections. Clin Infect Dis 2005;41:1373-1406. 
114.  US Department of Health and Human Services, Food and Drug 
Administration, Center for Drug Evaluation and Research 
(CDER). Guidance for industry: uncomplicated and complicated skin 
and skin structure infections—developing antimicrobial drugs for 
treatment. 
115. Meleney F. Hemolytic streptococcus gangrene. Arch Surg 1924; 
9: 317-31 
116. McHenry CR, Piotrowski JJ, Petrinic D, Malangoni MA. 
Determinants of mortality for necrotizing soft-tissue infections. Ann 
Surg 1995; 221(5): 558-63; discussion 63-5 
117. Wong CH, Chang HC, Pasupathy S, Khin LW, Tan JL, Low CO. 
Necrotizing fasciitis: clinical presentation, microbiology, and 
determinants of mortality. J Bone Joint Surg 2003; 85A(8): 1454-60 
128 
 
118. Singh G, Ray P, Sinha SK, Adhikary S, Khanna SK. 
Bacteriology of necrotizing infections of soft tissues. Aust N Z J 
Surg 1996; 66(11): 747-50. 
119.  Tang WM, Ho PL, Fung KK, Yuen KY, Leong JC. Necrotising 
fasciitis of a limb. J Bone Joint Surg 2001; 83-B(5): 709-14 
120. Elliott DC, Kufera JA, Myers RA. Necrotizing soft tissue 
infections. Risk factors for mortality and strategies for management. 
Ann Surg 1996; 224(5): 672-83 
121. Eckmann C K, P, Psathakis D. Results of standardized therapy of 
necrotizing fasciitis. Br J Surg 1997; 88. Supplement 2 
122. Bosshardt TL HV, Organ CH Jr. Necrotizing soft-tissue 
infections. Archives Surgery 1996; 131(8): 846-54. 
123.  Fustes MA, Gutierrez CP, Duran MC, Orozco CL, Tamayo SL, 
Ruiz MR. Necrotizing fasciitis: report of 39 pediatric cases. Arch 
Dermatol 2002; 138(7): 893-9 
124. Darke SG, King AM, Slack WK. Gas gangrene and related 
infection: classification, clinical features and aetiology, management 
and mortality: a report of 88 cases. Br J Surg 1977; 64:104-112. 
129 
 
125. Clayton MD, Fowler JE, Sharifi R, et al. Causes, presentation and 
survival of fifty-seven patients with necrotizing fasciitis of the male 
genitalia. Surg Gynecol Obstet 1990; 170:49-55.  
126. Patino JF, Castro D. Necrotizing lesions ofsoft tissues: a review. 
World J Surg 1991; 15:235-239. 
 
